You are here:

Site-map

Please click on the section required to navigate directly to that section.

1 Home
2 About Us & Subscriptions
2.1 Subscription Information
2.2 Subscribe to the Journal
2.3 Single Article Purchases
2.4 Register with Us
2.5 Copyright and Disclaimer
2.6 Advertising
2.6.1 Advertising Policy
3 Editorial Board
3.1 Editors
3.2 Editorial Board Members
3.3 Past Editors
4 Contents
4.1 2016
4.1.1 Volume 25 Number 6 November 2016
4.1.1.1 AORTIC VALVE DISEASE
4.1.1.1.1 TAVR in Intermediate-Risk Patients: A Review of the PARTNER 2 Trial and its Future Implications
4.1.1.1.2 Morphological and Clinical Findings of Explanted Carpentier-Edwards Perimount Pericardial Valve in the Aortic Position
4.1.1.1.3 Risk Factors for Permanent Pacemaker after Implantation of Surgical or Percutaneous Self-Expanding Aortic Prostheses
4.1.1.1.4 Clinical Outcomes in Different Types of Aortic Stenosis as Assessed by Doppler Echocardiography
4.1.1.1.5 Long-Term Outcome of the Sorin Freedom SOLO Stentless Aortic Valve
4.1.1.2 MITRAL VALVE DISEASE
4.1.1.2.1 Simple Interrupted Suturing for Redo Mitral Valve Replacement
4.1.1.2.2 Early Results of Rheumatic Mitral Valve Repair
4.1.1.2.3 A Systematic Review and Meta-Analysis of Outcomes Following Mitral Valve Surgery in Patients with Significant Functional Mitral Regurgitation and Left Ventricular Dysfunction
4.1.1.2.4 Association of Transforming Growth Factor-β Superfamily Genes with Non-Regression of Pulmonary Artery Hypertension Following Balloon Mitral Valvotomy: A Pilot Study
4.1.1.2.5 Effects of Surgical Techniques on Long-Term Results in Patients with Degenerative Mitral Valve Bileaflet Prolapse
4.1.1.2.6 Frequency, Mechanism and Severity of Mitral Regurgitation: Are There any Differences Between Primary and Secondary Mitral Regurgitation?
4.1.1.3 TRICUSPID VALVE DISEASE
4.1.1.3.1 Tricuspid Valve Repair for Infective Endocarditis with Periannular Involvement: Complete Valve Reconstruction
4.1.1.4 DEVICE EVALUATION
4.1.1.4.1 When Not to Go SOLO? Contraindications Based on Implant Experience
4.1.1.5 CASE REPORT
4.1.1.5.1 Treatment of Myocardial Infarction and Mitral Regurgitation in a Patient with Congenitally Corrected Transposition of the Great Arteries
4.1.1.5.2 Valve Dehiscence after Bentall Procedure: The Detrimental Traits of Propionibacterium
4.1.1.5.3 Left Ventricular Outflow Tract Obstruction and Systolic Anterior Motion of the Mitral Valve in the Absence of Hypertrophic Cardiomyopathy
4.1.1.5.4 Multiple Valvular Complications of Hypereosinophilic Syndrome
4.1.1.5.5 Stroke Related to Transcatheter Heart Valve Thrombosis
4.1.1.5.6 Stroke Related to Transcatheter Heart Valve Thrombosis
4.1.1.5.7 Stroke Related to Transcatheter Heart Valve Thrombosis
4.1.1.5.8 Stroke Related to Transcatheter Heart Valve Thrombosis
4.1.1.5.9 Non-Bacterial Thrombotic Endocarditis of Aortic Valve due to Hypereosinophilic Syndrome
4.1.1.6 LETTER TO THE EDITOR
4.1.1.6.1 Acute Type A Aortic Dissection: Beyond the Diameter
4.1.2 Volume 25 Number 5 September 2016
4.1.2.1 AORTIC VALVE DISEASE
4.1.2.1.1 Cardiac Fibrosis in Aortic Stenosis and Hypertensive Heart Disease Assessed by Magnetic Resonance T1 Mapping
4.1.2.1.2 Markers of Lipid Metabolism Do Not Correlate with the Expression of Aortopathy in Patients with Bicuspid Aortic Valve Disease
4.1.2.1.3 Prevalence and Impact of Prosthesis-Patient Mismatch Following Surgical Aortic Valve Replacement for Pure Aortic Regurgitation
4.1.2.1.4 The Impact of Gender on Outcomes Following Transcatheter Aortic Valve Implantation: True Effect or Bias?
4.1.2.1.5 Immediate, Early and Late Failure after Transcatheter Aortic Valve Implantation: How to Deal with the Inoperable?
4.1.2.1.6 Bicuspid Aortic Valve: A Review of its Genetics and Clinical Significance
4.1.2.1.7 Ablation of Macro-Re-Entrant Atrial Arrhythmia Late after Surgical Aortic Valve Replacement
4.1.2.2 MITRAL VALVE DISEASE
4.1.2.2.1 Altered Plasma MicroRNA Expression in Patients with Mitral Chordae Tendineae Rupture
4.1.2.2.2 Mitral Patient-Prosthesis Mismatch Predicts Suboptimal Hemodynamic Recovery after Mitral Valve Replacement
4.1.2.3 TRICUSPID VALVE DISEASE
4.1.2.3.1 Porcine Tricuspid Valve Anatomy and Human Compatibility: Relevance for Preclinical Validation of Novel Valve Interventions
4.1.2.4 THROMBOSIS EMBOLISM AND BLEEDING
4.1.2.4.1 Improved Pig Model to Evaluate Heart Valve Thrombosis
4.1.2.5 RHEUMATIC HEART DISEASE
4.1.2.5.1 NT-ProBNP as a Potential Marker of Left Atrial Dysfunction in Rheumatic Mitral Stenosis: Correlation with Left Atrial Function after PBMV
4.1.2.5.2 Rheumatic Fever and Rheumatic Heart Disease: Collaboration Patterns and Research Core Topics
4.1.2.6 DEVICE EVALUATION
4.1.2.6.1 Clinical Presentation and Value of Echocardiography in the Diagnosis of Freestyle Aortic Bioprosthesis Leaflet Tears: A Retrospective Study
4.1.2.6.2 Dysfunction of an On-X Heart Valve by Pannus
4.1.2.7 CASE REPORTS
4.1.2.7.1 A Simple Technique for Aortic Root Dissection and Massive Aortic Regurgitation Repair after Blunt Chest Trauma
4.1.2.7.2 Aortic Valve Replacement in Dextrocardia and Anomalous Origin of the Coronary Artery
4.1.2.7.3 Atrial Septostomy as a Bridge to Replace a Thrombosed Mechanical Aortic Valve Requiring Extracorporeal Membrane Oxygenation
4.1.2.7.4 Atrial Septostomy as a Bridge to Replace a Thrombosed Mechanical Aortic Valve Requiring Extracorporeal Membrane Oxygenation
4.1.2.7.5 Percutaneous Pulmonary Valve Implantation in the Patched Right Ventricular Outflow Tract 51 Years after Surgical Repair for Tetralogy of Fallot
4.1.2.8 BRIEF COMMUNICATION
4.1.2.8.1 Recommendations for Valve Replacement in Ischemic Mitral Regurgitation with Compromised Ventricle
4.1.3 Volume 25 Number 4 July 2016
4.1.3.1 AORTIC VALVE DISEASE
4.1.3.1.1 Evaluation of Aortic Paravalvular Leak: A Special Reference for Anatomical Localization
4.1.3.1.2 Morphological Characteristics and Calcification of the Native Aortic Valve and the Relation to Significant Aortic Regurgitation after CoreValve TAVI
4.1.3.1.3 CoreValve Prosthesis Depth: What is the Optimal Measurement Target?
4.1.3.1.4 Suture Forces for Closure of Transapical Transcatheter Aortic Valve Replacement: A Mathematical Model
4.1.3.1.5 Video 1 for Article: Suture Forces for Closure of Transapical Transcatheter Aortic Valve Replacement: A Mathematical Model
4.1.3.1.6 Video 2 for Article: Suture Forces for Closure of Transapical Transcatheter Aortic Valve Replacement: A Mathematical Model
4.1.3.1.7 Video 3 for Article: Suture Forces for Closure of Transapical Transcatheter Aortic Valve Replacement: A Mathematical Model
4.1.3.1.8 Hospital Readmission after Aortic Valve Replacement: Impact of Preoperative Heart Failure
4.1.3.1.9 Successful Surgical Treatment of a Huge Candida albicans Aortic Fungus Ball with Pseudoaneurysm
4.1.3.1.10 Root Replacement for Graft Infection Using an All-Biologic Xenopericardial Conduit
4.1.3.1.11 The Modified Bentall Procedure: A Single-Institution Experience in 249 Patients with a Maximum Follow Up of 21.5 Years
4.1.3.1.12 A Patient with Quadricuspid Aortic Valve and Ischemic Stroke
4.1.3.2 MITRAL VALVE DISEASE
4.1.3.2.1 Multiple Imaging Modalities Including Three-Dimensional Echocardiography in Left Ventricular Pseudoaneurysm After Mitral Valve Replacement
4.1.3.2.2 Video 1(a) for Artivle: Multiple Imaging Modalities Including Three-Dimensional Echocardiography in Left Ventricular Pseudoaneurysm After Mitral Valve Replacement
4.1.3.2.3 Video 1(b) for Article: Multiple Imaging Modalities Including Three-Dimensional Echocardiography in Left Ventricular Pseudoaneurysm After Mitral Valve Replacement
4.1.3.2.4 Video 2(a) for Article: Multiple Imaging Modalities Including Three-Dimensional Echocardiography in Left Ventricular Pseudoaneurysm After Mitral Valve Replacement
4.1.3.2.5 Video 2(b) for Article: Multiple Imaging Modalities Including Three-Dimensional Echocardiography in Left Ventricular Pseudoaneurysm After Mitral Valve Replacement
4.1.3.2.6 Matrix Metalloproteinases (MMPs), Their Genetic Variants and miRNA in Mitral Valve Diseases: Potential Biomarker Tools and Targets for Personalized Treatments
4.1.3.2.7 Hemodynamic Improvement at Three Months after MitraClip® Treatment in End-Stage Heart Failure Patients with Functional Mitral Regurgitation
4.1.3.2.8 Mitral Valve Re-Repair in an Adult Patient Having Undergone Mitral Ring Annuloplasty at Five Years of Age
4.1.3.3 MINIMALLY INVASIVE SURGERY
4.1.3.3.1 Outcomes of Minimally Invasive Valve Surgery in Patients with Multiple Previous Cardiac Operations
4.1.3.4 CASE REPORTS
4.1.3.4.1 A Left-to-Right Shunt After Transfemoral TAVR Using Edwards SAPIEN 3
4.1.3.4.2 New-Onset Hemolytic Anemia after Percutaneous Paravalvular Leak Closure
4.1.3.4.3 Video 1 for Article: New-Onset Hemolytic Anemia after Percutaneous Paravalvular Leak Closure
4.1.3.4.4 Video 2 for Article: New-Onset Hemolytic Anemia after Percutaneous Paravalvular Leak Closure
4.1.3.4.5 Implantation of a SAPIEN 3 Valve in a Patient with Pure Aortic Regurgitation
4.1.3.4.6 Retrograde Snare Technique to Overcome Hostile Aortic Arch Anatomy During Transcatheter Aortic Valve Implantation
4.1.3.4.7 Right Coronary Artery and Left Anterior Descending Artery Occlusion after Aortic Valve Replacement
4.1.3.4.8 Percutaneous Closure of Massive Mitral Paravalvular Leak
4.1.3.4.9 A Perceval Valve in Active Infective Bioprosthetic Valve Endocarditis: Case Report
4.1.3.4.10 Mitral Valve Diverticulum Presenting with Severe Mitral Stenosis: Case Report
4.1.3.5 HOW TO DO IT
4.1.3.5.1 A New Artificial Chordae Implantation Method in Mitral Valve Surgery
4.1.3.6 LETTERS TO THE EDITOR
4.1.3.6.1 The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis
4.1.3.6.2 Chordal Shortening for Anterior Mitral Leaflet Prolapse and the Maze Procedure for Persistent Atrial Fibrillation
4.1.4 Volume 25 Number 3 May 2016
4.1.4.1 AORTIC VALVE DISEASE
4.1.4.1.1 Aortopathy in Bicuspid Aortic Valve Stenosis with Fusion of Right-Left versus Right-Non-Coronary Cusps: Are These Different Diseases?
4.1.4.1.2 Ascending Aortic Stiffness with Bicuspid Aortic Valve is Variable and Not Predicted by Conventional Parameters in Young Patients
4.1.4.1.3 Predictors of High Post-Procedural Gradients after Catheter-Based Aortic Valve Implantation Using Direct Flow Medical Bioprostheses
4.1.4.1.4 Quantitative Doppler for Estimation of Paravalvular Leakage after Transcatheter Aortic Valve Implantation
4.1.4.1.5 Patho-Histological Findings of Annular Rupture Related to Left Ventricular Outflow Tract (LVOT) Calcification Following Transcatheter Aortic Valve Replacement (TAVR)
4.1.4.1.6 Impact of Paravalvular Aortic Insufficiency on Left Ventricular Remodeling and Mortality after Transcatheter Aortic Valve Replacement
4.1.4.2 MITRAL VALVE DISEASE
4.1.4.2.1 Left Atrial and Left Ventricular Function and Remodeling Following Percutaneous Mitral Valve Repair
4.1.4.2.2 MitraClip®: Two Weeks after Implantation
4.1.4.2.3 Distant Position of Chordae from Coaptation Causes Mitral Regurgitation in Patients with Atrial Fibrillation
4.1.4.2.4 Treatment of Mitral Valve Regurgitation with an Open Rigid Annuloplasty Ring
4.1.4.3 TRICUSPID VALVE DISEASE
4.1.4.3.1 Re-Repair of Tricuspid Valve after Tricuspid Suture Annuloplasty: An Analysis of the Causes for Reoperation and its Durability
4.1.4.4 CARCINOID HEART VALVE DISEASE
4.1.4.4.1 Valve Replacement in Patients with Carcinoid Heart Disease: Choosing the Right Valve at the Right Time
4.1.4.4.2 Results of Contemporary Valve Surgery in Patients with Carcinoid Heart Disease
4.1.4.5 INFECTIVE ENDOCARDITIS
4.1.4.5.1 Complicated Infective Endocarditis of a Mechanical Aortic Valve due to Propionibacterium acnes
4.1.4.5.2 Infective Endocarditis in Hemodialysis Patients
4.1.4.5.3 Seroprevalence of Q Fever in Patients Undergoing Heart Valve Replacement Surgery
4.1.4.6 MISCELLANEOUS
4.1.4.6.1 PGA (polyglycolic acid)-P4HB (poly-4-hydroxybutyrate)-Based Bioengineered Valves in the Rat Aortic Circulation
4.1.4.6.2 Video for Artivle: PGA (polyglycolic acid)-P4HB (poly-4-hydroxybutyrate)-Based Bioengineered Valves in the Rat Aortic Circulation
4.1.4.6.3 Prognostic Value of Neutrophil-to-Lymphocyte Ratio for Patients Undergoing Heart Valve Replacement
4.1.4.6.4 Conventional and Novel Predictors of Permanent Pacemaker after TAVI in Atrial Fibrillation Patients
4.1.5 Volume 25 Number 2 March 2016
4.1.5.1 AORTIC VALVE DISEASE
4.1.5.1.1 Contribution of Dobutamine Stress Echocardiography to the Diagnosis and Prognosis of Low-Flow/Low-Gradient Aortic Stenosis
4.1.5.1.2 Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
4.1.5.1.3 Sutureless Aortic Valve Replacement: An Easy and Safe Approach for Patients with Anomalous Left Circumflex Coronary Artery
4.1.5.1.4 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.5 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.6 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.7 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.8 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.9 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.10 Ventricular Septal Defect from Aortic Regurgitation Jet Lesion in Aortic Valve Infective Endocarditis
4.1.5.1.11 Transcatheter Aortic Valve Replacement in Type B Aortic Dissection
4.1.5.1.12 Prevalence of Late Functional Tricuspid Regurgitation in Degenerative Mitral Regurgitation Surgery
4.1.5.1.13 Acute Invasive Hemodynamic Effects of Transcatheter Aortic Valve Replacement
4.1.5.1.14 Predictability and Outcome of Vascular Complications after Transfemoral Transcatheter Aortic Valve Implantation
4.1.5.1.15 Aortic Regurgitation after TAVR: From Bad to Worse
4.1.5.1.16 Aortic Regurgitation after TAVR: From Bad to Worse
4.1.5.1.17 Aortic Regurgitation after TAVR: From Bad to Worse
4.1.5.1.18 Aortic Regurgitation after TAVR: From Bad to Worse
4.1.5.2 MITRAL VALVE DISEASE
4.1.5.2.1 Transcatheter Mitral Valve-in-Ring for Progressive Mitral Stenosis after Prior Repair with Annuloplasty: A Novel Balloon Sizing Technique
4.1.5.2.2 Transcatheter Mitral Valve-in-Ring for Progressive Mitral Stenosis after Prior Repair with Annuloplasty: A Novel Balloon Sizing Technique
4.1.5.2.3 Repair of Anterior Mitral Leaflet Prolapse: Comparison of Mid-Term Outcomes with Chordal Transposition and Chordal Replacement Techniques
4.1.5.2.4 An Unusual Case of Persistent Severe Pulmonary Artery Hypertension Following Balloon Mitral Valvuloplasty
4.1.5.2.5 The Presence of Left Atrial Thrombus is Associated with the Neutrophil-to-Lymphocyte Ratio in Patients with Rheumatic Mitral Valve Stenosis
4.1.5.3 TRICUSPID VALVE DISEASE
4.1.5.3.1 Underlying Rheumatic Disease: An Important Determinant of Outcome in Tricuspid Valve Repair
4.1.5.4 THROMBOSIS EMBOLISM and BLEEDING
4.1.5.4.1 Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy
4.1.5.4.2 Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy
4.1.5.4.3 Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy
4.1.5.4.4 Thrombolysis for Left-Sided Prosthetic Valve Thrombosis: Short- and Long-Term Outcomes
4.1.5.4.5 Thrombolysis for Left-Sided Prosthetic Valve Thrombosis: Short- and Long-Term Outcomes
4.1.5.4.6 Thrombolysis for Left-Sided Prosthetic Valve Thrombosis: Short- and Long-Term Outcomes
4.1.5.5 INFECTIVE ENDOCARDITIS
4.1.5.5.1 Broad-Range 16S rDNA PCR on Heart Valves in Infective Endocarditis
4.1.5.6 HOW TO DO IT
4.1.5.6.1 How to Do It - Implantation Technique for Newer-Generation Sutureless/Rapid-Deployment Aortic Valve Replacement
4.1.5.7 DEVICE EVALUATION
4.1.5.7.1 Surgical Management and Postoperative Outcomes of Mechanical Valve Dysfunction: A Six-Year, Single-Center Study
4.1.5.7.2 Excellence and Durability: A Normally Functioning Björk-Shiley Flat-Disc Prosthesis 42 Years Post Implantation
4.1.5.8 MISCELLANEOUS
4.1.5.8.1 MALDI Imaging Mass Spectrometry as a Lipidomic Approach to Heart Valve Research
4.1.5.8.2 The Immune Responses and Calcification of Bioprostheses in the α1,3-Galactosyltransferase Knockout Mouse
4.1.6 Volume 25 Number 1 January 2016
4.1.6.1 Valvular Heart Disease Epidemics
4.1.6.2 AORTIC VALVE DISEASE
4.1.6.2.1 Favorable Survival after Aortic Valve Replacement Compared to the General Population
4.1.6.2.2 Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Basilar Artery Ischemic Stroke Following Transfemoral Transcatheter Aortic Valve Implantation
4.1.6.2.3 Syphilitic Aortitis Presenting with Coronary Ostial Stenosis and Aortic Regurgitation
4.1.6.2.4 Immediate Outcomes of Aortic Valve Replacement with Sutureless versus Stentless Bioprosthesis
4.1.6.2.5 Value of Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction to Predict Adverse Outcome in Patients with Asymptomatic Aortic Stenosis
4.1.6.3 MITRAL VALVE DISEASE
4.1.6.3.1 Impact of Prosthesis-Patient Mismatch after Mitral Valve Replacement
4.1.6.3.2 Untreated Mitral Regurgitation Does Not Affect Survival of Elderly Patients Undergoing TAVI
4.1.6.3.3 Impact of Chronic Rheumatic Valve Diseases on Large Vessels
4.1.6.3.4 Impaired Left Ventricular Function Does Not Predict Worse Late Outcome after Isolated Mitral Valve Surgery
4.1.6.3.5 Triple Percutaneous Mitral Balloon Valvuloplasty for Patients with Recurrent Mitral Valve Stenosis: Long-Term Observations
4.1.6.4 TRICUSPID VALVE DISEASE
4.1.6.4.1 The Double-Orifice Valve Technique to Treat Tricuspid Valve Incompetence
4.1.6.5 INFECTIVE ENDOCARDITIS
4.1.6.5.1 Not So EASE-Y: How Often do Hospitalized Infective Endocarditis Patients Meet Criteria for Early Surgery?
4.1.6.6 REPLACEMENT DEVICE EVALUATION
4.1.6.6.1 Thrombocytopenia after Aortic Valve Replacement with Perceval S Sutureless Bioprosthesis
4.1.6.6.2 Biomechanical Properties of Fiber Bundle and Membrane Mesostructures of the Porcine Aortic Valve
4.1.6.6.3 Transcatheter Valve-in-Valve Implantation in a Degenerated Mitral Bioprosthesis Using a Trans-Septal Anterograde Approach and 3-D Transesophageal Echocardiography Guidance
4.1.6.6.4 Ventricular Embolization of Two Edwards SAPIEN XT Prosthetic Valves During Trans-Subclavian Aortic Valve Implantation
4.1.6.6.5 Experimental Study on the In-Vivo Heterotopic Transplantation of Aortic Valved Homografts after De-Endothelialization
4.1.6.6.6 Histopathological and Immunohistochemical Evaluation of Pannus Tissue in Patients with Prosthetic Valve Dysfunction
4.1.6.7 CASE REPORT
4.1.6.7.1 Quadruple Valve Reoperation after the Ross Procedure
4.1.6.8 MISCELLANEOUS
4.1.6.8.1 Abiotrophia defectiva Endocarditis Complicated by Ventricular Tachycardia
4.1.6.8.2 Left Atrial Reservoir Function in Symptomatic Versus Asymptomatic Patients with Moderate Mitral Stenosis
4.1.6.8.3 Analysis of the Early Results of 693 Patients Undergoing Valvular Reoperation Between 1993 and 2011
4.2 2015
4.2.1 Volume 24 Number 6 November 2015
4.2.1.1 AORTIC VALVE DISEASE
4.2.1.1.1 Repair of Bicuspid Aortic Valve Syndrome with Anomalous Right Coronary Artery in Osteogenesis Imperfecta
4.2.1.1.2 Aortic Valve Replacement in Redo-Scenarios: A Comparison Between Traditional Aortic Valve Replacement (TAVR) and Transapical-TAVR from Two Real-World Multicenter Registries
4.2.1.1.3 A Rare Aortic Valve Congenital Abnormality in Association with Coarctation of the Aorta
4.2.1.1.4 Bicuspid Aortic Valve and Aortic Root Morphology in Hispanic Patients
4.2.1.1.5 TAVI and Bicuspid Aortic Valve: Check the Inter-Commissural Space!
4.2.1.1.6 Right Anterior Mini-Thoracotomy: A 'New Gold Standard' for Aortic Valve Replacement?
4.2.1.1.7 Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis
4.2.1.1.8 Downward Displacement of the Aortic Annulus: Case Report and Literature Review
4.2.1.1.9 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.10 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.11 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.12 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.13 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.14 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.15 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.16 An Extreme Case of CoreValve Bioprosthesis Embolization into the Abdominal Aorta and of the Delivery Catheter Cone into the Right Internal Iliac Artery
4.2.1.1.17 Bicuspid Aortic Valve-Associated Ascending Thoracic Aortic Aneurysm: Patient-Specific Finite Element Analysis
4.2.1.1.18 Subcoronary Stentless Aortic Valves are Not Superior to Supra-Annular Stented Valves Regarding Turbulent Stress
4.2.1.2 MITRAL VALVE DISEASE
4.2.1.2.1 Effects of Mitral Balloon Valvuloplasty on Coronary Blood Flow and Flow Reserve
4.2.1.2.2 Mitral Valve Surgery in The Elderly: Should We Treat Atrial Fibrillation Too?
4.2.1.2.3 Annuloplasty Ring Size Determines Exercise-Induced Mitral Stenosis Severity after Valve Repair
4.2.1.2.4 Surgical Treatment of Posterior Mitral Valve Prolapse: Towards 100% Repair
4.2.1.3 REPLACEMENT VALVES
4.2.1.3.1 Clinical impact of a new bioprosthetic aortic valve: the St. Jude Medical Trifecta™
4.2.1.4 INFECTIVE ENDOCARDITIS
4.2.1.4.1 The Usefulness of Magnetic Resonance Imaging in the Diagnosis of Infectious Endocarditis
4.2.1.5 MISCELLANEOUS
4.2.1.5.1 Multiple Fibroelastoma: Search and You Will Find
4.2.1.5.2 Pasteurella multocida Infective Endocarditis
4.2.1.5.3 Surgical Thrombectomy of Mechanical Valve Thrombosis
4.2.2 Volume 24 Number 5 September 2015
4.2.2.1 EDITORIAL
4.2.2.1.1 Editorial: Shifting a Paradigm of Cardiac Surgery: From Minimally Invasive to Micro-Invasive
4.2.2.2 AORTIC VALVE DISEASE
4.2.2.2.1 Minimally Invasive Aortic Valve Replacement: Cost-Benefit Analysis of Ministernotomy Versus Minithoracotomy Approach
4.2.2.2.2 Quality of Life Shift after Aortic Valve Replacement in the Era of TAVI: Single-Center Class Comparison Study Between Different Procedural Techniques
4.2.2.2.3 Novel Method of Assessing Ascending Aorta with a Stenotic Bicuspid Aortic Valve
4.2.2.2.4 Intra- and Inter-Observer Reproducibility of Transcatheter Aortic Valve Replacement Planning Measurements by Multidetector Computed Tomography
4.2.2.2.5 Fate of Normally Functioning Bicuspid Aortic Valve in Patients Undergoing Ascending Aorta Surgery
4.2.2.3 MITRAL VALVE DISEASE
4.2.2.3.1 Prognostic Implication of Three-Dimensional Mitral Valve Tenting Geometry in Dilated Cardiomyopathy
4.2.2.3.2 Cusp-Level Chordal Shortening for Non-Rheumatic Mitral Anterior Leaflet Prolapse in a Patient with Persistent Atrial Fibrillation
4.2.2.3.3 Managing Ventricular Septal Defect with Associated Aortic Regurgitation: Two Decades of Experience
4.2.2.4 DEVICE EVALUATION
4.2.2.4.1 A Comprehensive Fluid Dynamic and Geometric Study for an “In-Vitro” Comparison of Four Surgically Implanted Pericardial Stented Valves
4.2.2.4.2 Evaluation of p53 Polymorphism in Patients with Pannus-Derived Prosthetic Dysfunction
4.2.2.4.3 Expression and Localization of Granzymes and Perforin in Human Calcific Aortic Valve Disease
4.2.2.4.4 Degenerative Calcification of Pericardial Bioprostheses: Comparison of Five Implantation Methods in a Rabbit Model
4.2.2.5 MISCELLANEOUS
4.2.2.5.1 Heart Transplant in Patients with Predominantly Rheumatic Valvular Heart Disease
4.2.2.5.2 Transcatheter Aortic Valve Implantation in Patients at Extremely High Risk of Perioperative Mortality
4.2.2.5.3 Balloon-Expandable and Self-Expanding Transcatheter Heart Valves: Friend or Foe?
4.2.2.6 ATRIOVENTRICULAR VALVES
4.2.2.6.1 Force Required to Cinch the Tricuspid Annulus: An Ex-Vivo Study
4.2.2.6.2 Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug
4.2.2.6.3 Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug
4.2.2.6.4 Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug
4.2.2.6.5 Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug
4.2.3 Volume 24 Number 4 July 2015
4.2.3.1 AORTIC VALVE DISEASE
4.2.3.1.1 Valve Replacement for Moderate Aortic Stenosis in Octogenarians Undergoing Revascularization
4.2.3.1.2 Aortic Annulus Diameter Affects Durability of the Repaired Bicuspid Aortic Valve
4.2.3.1.3 Direct Aortic Access Transcatheter Aortic Valve Replacement: Three-Dimensional Computed Tomography Planning and Real-Time Fluoroscopic Image Guidance
4.2.3.1.4 Short-Term Outcomes with Direct Aortic Access for Transcatheter Aortic Valve Replacement
4.2.3.1.5 Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction
4.2.3.1.6 Aortic Annulus Rupture During TAVI: A Therapeutic Dilemma in the Inoperable Patient
4.2.3.1.7 Aortic Annulus Rupture During TAVI: A Therapeutic Dilemma in the Inoperable Patient
4.2.3.1.8 Aortic Annulus Rupture During TAVI: A Therapeutic Dilemma in the Inoperable Patient
4.2.3.1.9 Aortic Annulus Rupture During TAVI: A Therapeutic Dilemma in the Inoperable Patient
4.2.3.1.10 Aortic Annulus Rupture During TAVI: A Therapeutic Dilemma in the Inoperable Patient
4.2.3.1.11 The Impact of Transcatheter Aortic Valve Implantation on Mitral Regurgitation Regression in High-Risk Patients with Aortic Stenosis
4.2.3.1.12 Evaluation of the Role of Oxidative Stress in Degenerative Aortic Stenosis
4.2.3.1.13 C4b-Binding Protein Deposition is Induced in Diseased Aortic Heart Valves, Coinciding with C3d
4.2.3.1.14 Myocardial and Cardiocirculatory Reserve in Asymptomatic Aortic Stenosis and Preserved Ejection Fraction
4.2.3.1.15 Sigmoid Septum and Balloon-Expandable Transcatheter Aortic Valve Replacement: A Cautionary Tale
4.2.3.2 MITRAL VALVE DISEASE
4.2.3.2.1 The So-Called ‘Eclipsed’ Mitral Regurgitation
4.2.3.2.2 Early and Late Outcomes After Minimally Invasive Mitral Valve Repair Surgery
4.2.3.3 REPLACEMENT DEVICE EVALUATION
4.2.3.3.1 Does the Homograft for RVOT Reconstruction in Ross Patients Fare Better than for Non-Ross Patients? A Single-Center Experience
4.2.3.3.2 Feasibility of Valve-in-Valve Procedure for Degenerated St. Jude Medical Trifecta™ Bioprosthesis
4.2.3.3.3 A Matched-Paired Comparative Analysis of the Hemodynamics of the Trifecta and Perimount Aortic Bioprostheses
4.2.3.4 MISCELLANEOUS
4.2.3.4.1 The Role of Interleukin-13 in Patients with Rheumatic Valvular Fibrosis: A Clinical and Histological Study
4.2.3.4.2 Incremental Value of Cardiac Magnetic Resonance for Assessing Pulmonic Valve Regurgitation
4.2.3.4.3 Prophylactic Tricuspid Annuloplasty in Patients Undergoing Double Valve Replacement
4.2.3.5 CASE REPORT
4.2.3.5.1 Aortic Root Enlargement with Ascending-to-Descending Aortic Bypass in Repair of Coarctation
4.2.3.5.2 Conventional Aortic Valve Replacement after Displacement of a Percutaneously Implanted Aortic Prosthesis: Case Report
4.2.3.5.3 Double-Orifice Mitral Valve in an Eight-Year-Old Boy
4.2.3.5.4 Surgery for Congenital Tricuspid Valve Cleft: Tricuspid Valve Repair with Neochordae and Annuloplasty
4.2.4 Volume 24 Number 3 May 2015
4.2.4.1 AORTIC VALVE DISEASE
4.2.4.1.1 Determinants of Left Ventricular Mass Regression in Patients with Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
4.2.4.1.2 Analysis of Specified Bernoulli Constant for Semilunar Valve Stenosis in Humans
4.2.4.1.3 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.4 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.5 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.6 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.7 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.8 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.9 Concurrent Transcatheter Aortic Valve Implantation and Percutaneous Transvenous Mitral Commissurotomy for Totally Percutaneous Treatment of Combined Severe Rheumatic Aortic and Mitral Stenosis
4.2.4.1.10 Reimplantation Technique: A New Approach to Increase Aortic Valve Coaptation
4.2.4.1.11 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.12 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.13 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.14 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.15 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.16 Gerbode Defect as a Result of Fungal Aortic Valve Endocarditis
4.2.4.1.17 Results and Quality of Life after Minimally Invasive Ross Procedure
4.2.4.1.18 Aortic Valve Replacement in Patients with End-Stage Liver Disease: A Modified Perfusion Concept in High-Risk Patients
4.2.4.1.19 Large Abdominal Aortic Aneurysm in a High-Risk Surgical Patient: Combined Percutaneous Transfemoral TAVI and EVAR Procedure
4.2.4.1.20 Emergent Percutaneous Biventricular Support during Transcatheter Aortic Valve Replacement
4.2.4.2 MITRAL VALVE DISEASE
4.2.4.2.1 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.2 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.3 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.4 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.5 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.6 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.7 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.8 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.9 Percutaneous Mitral Valve Repair with the MitraClip System in Mitral Regurgitation Due to Mitral Annular Calcification
4.2.4.2.10 Mitral Valve Replacement with Half-and-Half Technique for Recurrent Mitral Paravalvular Leakage
4.2.4.2.11 Vanishing V-Wave: Percutaneous Edge-to-Edge Repair for Severe Mitral Regurgitation
4.2.4.2.12 Sleep Apnea in Patients with Rheumatic Mitral Stenosis
4.2.4.3 TRICUSPID VALVE DISEASE
4.2.4.3.1 The Forgotten (Tricuspid) Valve: Third Time, Right Time
4.2.4.3.2 Asymptomatic Tricuspid Stenosis Following a Complex Lead Extraction Procedure
4.2.4.3.3 Tricuspid Valve Repair with Pericardial Tube Placement via a Right Minithoracotomy
4.2.4.4 REPLACEMENT VALVES
4.2.4.4.1 First Explantation of Direct Flow Medical Transcatheter Valve
4.2.4.4.2 Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Deterioration Using the Valve-in-Valve Technique
4.2.4.4.3 Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Deterioration Using the Valve-in- Valve Technique
4.2.4.4.4 Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Deterioration Using the Valve-in- Valve Technique
4.2.4.4.5 Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Deterioration Using the Valve-in- Valve Technique
4.2.4.4.6 A Case Series of Obstructive Prosthetic Mitral Valve Thrombosis, Successfully Treated with Low-Dose, Slow Infusion Tissue-Type Plasminogen Activator
4.2.4.4.7 Hemodynamic comparison between Trifecta and Freestyle valves implanted in small aortic roots. One-year echocardiographic results from a prospective randomized study
4.2.4.5 VALVE REPLACEMENT AND PREGNANCY
4.2.4.5.1 Ten Years’ Experience of Pregnancy Outcomes in Women with Cardiac Valvulopathies: Are Valve Prostheses Worst?
4.2.4.5.2 Management of Prosthetic Thrombosis During Pregnancy: Importance of a Multidisciplinary Approach
4.2.4.6 MISCELLANEOUS
4.2.4.6.1 Radical Resection of Cardiac Angiosarcoma with Atrioventricular Reconstruction
4.2.4.6.2 Pulmonary Valvuloplasty by Autologous Pericardium in a Patient with Active Infectious Endocarditis and Osler’s Disease
4.2.4.6.3 Effectiveness of Anti-Calcification Technologies in a Rabbit Model
4.2.4.6.4 Computational Hemodynamic Investigation of Bileaflet and Trileaflet Mechanical Heart Valves
4.2.4.6.5 Quantitative Cardiology: Back to Square One
4.2.5 Volume 24 Number 2 March 2015
4.2.5.1 AORTIC VALVE DISEASE
4.2.5.1.1 Pathology of Balloon-Expandable and Self-Expanding Stents Following MRI-Guided Transapical Aortic Valve Replacement
4.2.5.1.2 Aggravating Factors Associated with the Severity of Aortic Regurgitation and Clinical Characteristics of Patients with Quadricuspid Aortic Valve
4.2.5.1.3 Valvulo-Arterial Impedance is the Best Mortality Predictor in Asymptomatic Aortic Stenosis Patients
4.2.5.1.4 Clinical Value of Ankle-Brachial Index in Asymptomatic Aortic Stenosis Patients
4.2.5.1.5 Iatrogenic Mitral Valve Chordal Rupture During Placement of an Inflatable and Repositionable Percutaneous Aortic Valve Prosthesis
4.2.5.1.6 Transaortic Aortomitral Junction Reconstruction and Mitral Valve Leaflet Repair for Recurrent Endocarditis
4.2.5.1.7 Impella-Assisted Balloon Aortic Valvuloplasty as a Bridge to Transcatheter Aortic Valve Replacement: Non-Contrast Approach
4.2.5.1.8 The Impact of a Minimally Invasive Approach on Reoperative Aortic Valve Replacement
4.2.5.1.9 Aortic Sutureless Perceval Valve for Small Root in Concomitant Mitral Valve Replacement
4.2.5.1.10 The Effect of oxLDL on Aortic Valve Calcification via the Wnt/β-catenin Signaling Pathway: An Important Molecular Mechanism
4.2.5.2 MITRAL VALVE DISEASE
4.2.5.2.1 Mid-Term Results for a Patch Valvuloplasty Technique to Correct Posterior Leaflet Prolapse
4.2.5.2.2 Evaluation of the Effect of Percutaneous Mitral Balloon Valvuloplasty on Left Ventricular Systolic Function via Strain and Strain Rate in Patients with Isolated Rheumatic Mitral Stenosis
4.2.5.3 REPLACEMENT VALVE EVALUATION
4.2.5.3.1 Evaluation of Prosthetic Valve Thrombosis by 64-Row Multi- Detector Computed Tomography
4.2.5.3.2 Aortic Sutureless Bioprosthesis Implantation Following Degeneration of a SOLO Stentless Valve
4.2.5.3.3 Transcatheter Aortic Valve-In-Valve Implantation for Severe Bioprosthetic Stenosis after Bentall Operation Using a Homograft in a Patient with Behçet’s Disease
4.2.5.3.4 Video 1: Transesophageal echocardiography after additional inflation (long-axis)
4.2.5.3.5 Video 2: Transesophageal echocardiography after additional inflation (short-axis)
4.2.5.3.6 Age-Related Reoperation Rate after the Ross Procedure: A Report from the German Ross Registry
4.2.5.4 LIBMAN-SACKS ENDOCARDITIS
4.2.5.4.1 Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Undergoing Cardiac Valve Surgery
4.2.5.4.2 Coagulase-Negative Staphylococcus Infective Endocarditis in a Lupus Patient with Libman-Sacks Endocarditis
4.2.5.5 PATHOLOGICAL ANATOMY
4.2.5.5.1 Comparison of Aortic Valve Annulus Diameter Determination through 3-Dimensional Transesophageal Echo with Cardiac MDCT and Assessment of Predictors for Annulus Sizing
4.2.5.6 PULMONARY AUTOGRAFT
4.2.5.6.1 Ross Procedure in Adults: Is Reoperation a Real Concern?
4.2.5.7 MISCELLANEOUS
4.2.5.7.1 Feto-Maternal Outcomes of Urgent Open-Heart Surgery During Pregnancy
4.2.5.8 CASE REPORT
4.2.5.8.1 Surgery for a Quadricuspid Aortic Valve: Case Report and Comprehensive Review of the Literature
4.2.5.8.2 Transcatheter Aortic Valve Implantation in a Patient with Myelofibrosis and Severe Thrombocytopenia
4.2.5.8.3 Triple Prosthetic Valve Dysfunction 30 Years after Surgery
4.2.5.8.4 Video 1: Transesophageal echocardiography, long-axis view, color Doppler. The PMV hemi-disc exhibits restricted opening
4.2.5.8.5 Video 2: Cinefluoroscopy, left anterior oblique (LAO) cranial PMV view. Restricted hemi-disc opening is depicted
4.2.5.8.6 Video 3: Cinefluoroscopy, left anterior oblique (LAO) caudal PTV view. Intermittent restriction of PTV hemi-disc opening
4.2.5.8.7 Video 4: Cinefluoroscopy, right anterior oblique (RAO) cranial PAV view. Normally opening PAV hemi-disc
4.2.5.8.8 Papillary Fibroelastoma Involving Chordae of the Mitral Valve with Two Aortic Valve Excrescences
4.2.6 Volume 24 Number 1 January 2015
4.2.6.1 AORTIC VALVE DISEASE
4.2.6.1.1 The Konno Procedure in Redo Aortic Valve Replacement after the Nicks Procedure
4.2.6.1.2 Long-Term Results after Aortic Valve-Sparing-Reimplantation Operation (David) in Bicuspid Aortic Valve
4.2.6.1.3 Prosthesis-Specific Predictors of Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement: Impact of Calcification and Sizing on Balloon-Expandable versus Self-Expandable Transcatheter Heart Valves
4.2.6.1.4 High Transcatheter Valve Replacement May Reduce Washout in the Aortic Sinuses: An In-Vitro Study
4.2.6.2 MITRAL VALVE DISEASE
4.2.6.2.1 Surgical Treatment of Functional Ischemic Mitral Regurgitation
4.2.6.2.2 Minimally Invasive Mitral Valve Replacement and Transfemoral Aortic Valve Implantation
4.2.6.2.3 Mitral Valve Repair is Feasible Following Extensive Decalcification and Reconstruction of the Atrioventricular Groove
4.2.6.2.4 A New Type of Mitral Valve Operation Using a Novel Stentless Mitral Valve made from Autologous Pericardium for Unrepairable Valve
4.2.6.2.5 Simultaneous Double Clipping Delivery Guide Strategy in Complex Mitral Regurgitation
4.2.6.3 DEVICE EVALUATION
4.2.6.3.1 Long-Term Clinical Outcomes of Silzone Era St. Jude Medical Mechanical Heart Valves
4.2.6.3.2 Cryoprotective Effect and Optimal Concentration of Trehalose on Aortic Valve Homografts
4.2.6.3.3 Outcome of Standard and Bicuspidalized Cryopreserved Homografts for Primary Right Ventricular Outflow Tract Reconstruction
4.2.6.4 MISCELLANEOUS
4.2.6.4.1 Trans-Septal Approach for Hypertrophic Obstructive Cardiomyopathy
4.2.6.4.2 Non-Cytotoxic Crosslinkers for Heart Valve Tissue Engineering
4.2.6.4.3 Advanced Integrity Preservation Technology Reduces Bioprosthesis Calcification While Preserving Performance and Safety
4.2.6.4.4 Carcinoid Heart Valve Disease: Transcatheter Pulmonary Valve-In-Valve Implantation in Failing Biological Xenografts
4.2.6.4.5 Generation of Simulated Calcific Lesions in Valve Leaflets for Flow Studies
4.2.6.5 CASE REPORT
4.2.6.5.1 Osteopetrosis: A Case of ‘Hostile Chest’ Associated with Symptomatic Aortic Valve Stenosis
4.2.6.5.2 A Fatal Case of Endocarditis on CoreValve ReValving System Caused by Enterococcus faecium Complicated by Iatrogenic Pancytopenia and Subacute Disseminated Intravascular Coagulation
4.2.6.5.3 A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.4 Movie 1 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.5 Movie 2 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.6 Movie 3 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.7 Movie 4 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.8 Movie 5 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.9 Movie 6 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.10 Movie 7 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.2.6.5.11 Movie 8 for Article: A Case of Iatrogenic Chordal Rupture after Transcatheter Aortic Valve Implantation Procedure Requiring a Second Valve
4.3 2014
4.3.1 Volume 23 Number 6 November 2014
4.3.1.1 AORTIC VALVE DISEASE
4.3.1.1.1 Determinants of Persistent or Recurrent Congestive Heart Failure after Contemporary Surgical Aortic Valve Replacement
4.3.1.1.2 Minimally Invasive Aortic Valve Replacement in Octogenarians Performed via a Right Anterior Thoracotomy Approach
4.3.1.1.3 Post-Procedural Arterial Hypertension: Implications for Clinical Outcome after Transcatheter Aortic Valve Implantation
4.3.1.1.4 Modeling Study of Aortic Root for Ross Procedure: A Structural Finite Element Analysis
4.3.1.2 MITRAL VALVE DISEASE
4.3.1.2.1 Does the Number of Redo Mitral Valve Replacements for Structural Valve Deterioration affect Early and Late Outcomes? Experience from 114 Reoperative Cases
4.3.1.2.2 Asymmetric Ring Annuloplasty for Ischemic Mitral Regurgitation: Early and Mid-Term Outcomes
4.3.1.2.3 Progression of Degenerative Mitral Stenosis: Insights From a Cohort of 254 Patients
4.3.1.2.4 A Model of Ischemic Mitral Regurgitation in Pigs with Three-Dimensional Echocardiographic Assessment
4.3.1.2.5 Real-World Echocardiography in Patients Referred for Mitral Valve Surgery: The Gap Between Guidelines and Clinical Practice
4.3.1.2.6 Effect of Mitral Annuloplasty Device Shape and Size on Leaflet and Myofiber Stress Following Repair of Posterior Leaflet Prolapse: A Patient-Specific Finite-Element Simulation
4.3.1.3 INFECTIVE ENDOCARDITIS
4.3.1.3.1 Latent Q Fever Endocarditis in Patients Undergoing Routine Valve Surgery
4.3.1.3.2 Efficacy of Nafamostat Mesilate as Anticoagulation During Cardiopulmonary Bypass for Early Surgery in Patients with Active Infective Endocarditis Complicated by Stroke
4.3.1.3.3 Determinants for Increased Resource Utilization after Surgery for Prosthetic Valve Endocarditis
4.3.1.4 MISCELLANEOUS
4.3.1.4.1 Permanent Lone Atrial Fibrillation and Atrioventricular Valve Regurgitation: May the Former Lead to the Latter?
4.3.1.4.2 Patient-Specific Finite Element Analysis of Ascending Thoracic Aortic Aneurysm
4.3.1.4.3 Double Arterial Perfusion Strategy for Acute Type A Dissection after Extra-Anatomic Bypass for Aortic Coarctation
4.3.1.4.4 Platelet Activation after Sorin Freedom Solo Valve Implantation: A Comparative Study with Carpentier-Edwards Perimount Magna
4.3.1.4.5 Minimally Invasive Approach for Isolated Tricuspid Valve Surgery
4.3.1.4.6 Papillary Muscle Force Distribution after Total Tricuspid Reconstruction using Porcine Extracellular Matrix: In-Vitro Valve Characterization
4.3.1.4.7 Aortic Valve Replacement with the Perceval S Bioprosthesis: Single-Center Experience in 143 Patients
4.3.1.5 BRIEF COMMUNICATION
4.3.1.5.1 Quantitative Cardiology: Back to Square One
4.3.2 Volume 23 Number 5 September 2014
4.3.2.1 AORTIC VALVE DISEASE
4.3.2.1.1 Review: Optimal Timing of Valve Replacement in Asymptomatic Severe Aortic Stenosis
4.3.2.1.2 Transcatheter Aortic Valve Implantation with a Giant Vegetation Successfully Treated with Antibiotics: Insights into a New Group of Patients with Endocarditis
4.3.2.1.3 B-Type Natriuretic Peptide is a Strong Independent Predictor of Long-Term Outcome after Transcatheter Aortic Valve Implantation
4.3.2.1.4 A Novel In-Vitro Model of Human Aortic Valve Mineralization
4.3.2.1.5 Clinical Outcomes and Lessons Learned with Aortic Valve Repair in 508 Patients
4.3.2.1.6 Nuclear Factor-κB-Hypoxia-Inducible Factor-2 Pathway in Aortic Valve Stenosis
4.3.2.1.7 Prediction of 30-day Mortality after Transcatheter Aortic Valve Implantation: A Comparison of Logistic EuroSCORE, STS score, and EuroSCORE II
4.3.2.1.8 Video 1 for article: Transcatheter Aortic Valve Implantation with a Giant Vegetation Successfully Treated with Antibiotics: Insights into a New Group of Patients with Endocarditis
4.3.2.1.9 Video 2 for article: Transcatheter Aortic Valve Implantation with a Giant Vegetation Successfully Treated with Antibiotics: Insights into a New Group of Patients with Endocarditis
4.3.2.1.10 Video 3 for article: Transcatheter Aortic Valve Implantation with a Giant Vegetation Successfully Treated with Antibiotics: Insights into a New Group of Patients with Endocarditis
4.3.2.2 MITRAL VALVE DISEASE
4.3.2.2.1 Routine Cine-CMR for Prosthesis-Associated Mitral Regurgitation: A Multicenter Comparison to Echocardiography
4.3.2.2.2 Real-Time Three-Dimensional Transthoracic Echocardiography for Predicting Mitral Annuloplasty Ring Size
4.3.2.2.3 Mitral Regurgitation in Left Ventricular Noncompaction Cardiomyopathy Assessed by Cardiac MRI
4.3.2.2.4 Could Anterior Papillary Muscle Partial Necrosis Explain Early Mitral Valve Repair Failure?
4.3.2.3 TRICUSPID VALVE DISEASE
4.3.2.3.1 Early and Mid-term Outcomes of Aggressive Tricuspid Annuloplasty with the MC3 Ring
4.3.2.4 INFECTIVE ENDOCARDITIS
4.3.2.4.1 Stroke is Not a Treatment Dilemma for Early Valve Surgery in Active Infective Endocarditis
4.3.2.4.2 Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Infective Endocarditis: In-Hospital and Long-Term Clinical Results
4.3.2.4.3 Clinical, Echocardiographic and Microbiological Study, and Analysis of Outcomes of Infective Endocarditis in Tropical Countries: A Prospective Analysis from India
4.3.2.5 DEVICE EVALUATION
4.3.2.5.1 Early Hemodynamic Evaluation of Trifecta™ and Freestyle® Bioprostheses in Patients with a Small Aortic Root: Preliminary Results from a Prospective Randomized Study
4.3.2.5.2 Numerical Analysis of the Hemodynamic Performance of Bileaflet Mechanical Heart Valves at Different Implantation Angles
4.3.2.6 CASE REPORT
4.3.2.6.1 An Uncommon Case of Isolated Parachute-Like Asymmetric Mitral Valve in an Adult
4.3.2.6.2 Feasibility of Sutureless Valve Implantation in Reoperation for Degenerated 19 mm Aortic Valvular Bioprostheses
4.3.2.6.3 Hybrid Internal Mammary to Left Anterior Descending Bypass and Transaortic Transcatheter Aortic Valve Implantation: A New Treatment Option for Patients with Complex Disease
4.3.2.6.4 Cavernous Hemangioma of the Mitral Valve in an Adult Male Patient Successfully Treated with Surgical Resection: A Case Report
4.3.2.6.5 Video 1 for Article: An Uncommon Case of Isolated Parachute-Like Asymmetric Mitral Valve in an Adult
4.3.2.6.6 Video 2 for Article: An Uncommon Case of Isolated Parachute-Like Asymmetric Mitral Valve in an Adult
4.3.2.6.7 Video 3 for Article: An Uncommon Case of Isolated Parachute-Like Asymmetric Mitral Valve in an Adult
4.3.3 Volume 23 Number 4 July 2014
4.3.3.1 AORTIC VALVE DISEASE
4.3.3.1.1 The Role of Inorganic Pyrophosphate in Aortic Valve Calcification
4.3.3.1.2 Relation of Cuspal Asymmetry to Development of Aortic Stenosis in Adults with Tricuspid Aortic Valves
4.3.3.1.3 Relationship Between Bicuspid Aortic Valve Phenotype, Valvular Function, and Ascending Aortic Dimensions
4.3.3.1.4 Long-Term Outcomes after Aortic Valve Repair and Associated Aortic Root Reconstruction
4.3.3.1.5 Aortic Interleaflet Triangles Reshaping: Hydrodynamic, Kinematic and Morphological Effects in In-Vitro Analysis
4.3.3.1.6 Comparison of Myocardial Tagging and Feature Tracking in Patients with Severe Aortic Stenosis
4.3.3.1.7 ‘Paradoxical’ Low-Flow, Low-Gradient Severe Aortic Valve Stenosis: An Entity with Limited Improvement Following Transcatheter Aortic Valve Implantation
4.3.3.1.8 Aortic Dilation Rates in Patients with Biscuspid Aortic Valve: Correlations with Cusp Fusion Phenotype
4.3.3.1.9 The Use of Intra-Aortic Balloon Pump in Patients Undergoing Heart Valve Replacement: Outcome and Risk Analysis
4.3.3.1.10 Aortic Dimensions in Relation to Bicuspid and Tricuspid Aortic Valve Pathology
4.3.3.1.11 Surgical Reconstruction of Aortic Root in Marfan Syndrome Patients: A Systematic Review
4.3.3.1.12 Valvuloplasty with a Paclitaxel-Eluting Balloon Prevents Restenosis in an Experimental Animal Model of Aortic Stenosis
4.3.3.2 MITRAL VALVE DISEASE
4.3.3.2.1 Transcatheter Mitral Repair and Replacement: State of the Art and Future Directions
4.3.3.2.2 Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.2.3 Video 1 for Article: Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.2.4 Video 2 for Article: Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.2.5 Video 3 for Article: Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.2.6 Video 4 for Article: Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.2.7 Video 5 for Article: Ruptured Giant Mitral Valve Aneurysm: An Unexpected Finding in a Diabetic Patient with Dyspnea and New-Onset Atrial Fibrillation
4.3.3.3 PULMONARY VALVE DISEASE
4.3.3.3.1 Balloon Pulmonary Valvuloplasty in Adults: Immediate and Long-Term Outcomes
4.3.3.4 DEVICE ASSESSMENT
4.3.3.4.1 Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta™ Bioprosthetic Aortic Valve
4.3.4 Volume 23 Number 3 May 2014
4.3.4.1 AORTIC VALVE DISEASE
4.3.4.1.1 Calcium and Phosphorus Concentrations in Native and Decellularized Semilunar Valve Tissues
4.3.4.1.2 Quantification of Low-Gradient Severe Aortic Stenosis Using a Hybrid Approach Combining Doppler Echocardiography and Thermodilution
4.3.4.1.3 Relationship Between Left Ventricular Diastolic Function and Arterial Stiffness in Patients with Bicuspid Aortic Valve
4.3.4.1.4 Repositioning of an Intraventricular Dislocated Aortic Valve during Transcatheter Aortic Valve Implantation
4.3.4.1.5 Valve-Sparing Aortic Root Replacement in Patients with Marfan Syndrome Enrolled in the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
4.3.4.2 MITRAL VALVE DISEASE
4.3.4.2.1 Mitral Valvuloplasty: When the Art of Repair Meets the Biological Science
4.3.4.2.2 Mid-Term Results of Mitral Valve Repair with Autologous Pericardium in Pediatric Patients
4.3.4.2.3 Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults
4.3.4.3 DEVICE EVALUATION
4.3.4.3.1 Textile Heart Valve: First In-Vivo Experiment in the Aortic Position
4.3.4.3.2 Postoperative Conduction Disorders after Implantation of the Self-Expandable Sutureless Perceval S Bioprosthesis
4.3.4.3.3 Early In-Vivo Hemodynamic Comparison of Supra-Annular Aortic Bioprostheses: Trifecta™ versus Perimount Magna Ease
4.3.4.3.4 Excellent Mid-Term Durability of the On-X® Mechanical Aortic Valve in the Pulmonary Position with a Low International Normalized Ratio
4.3.4.3.5 A Single-Center Experience with the Sorin Mitroflow® Pericardial Aortic Valve: Hemodynamics up to Five Years
4.3.4.4 INFECTIVE ENDOCARDITIS
4.3.4.4.1 Right Anterior Minithoracotomy versus Median Sternotomy Surgery for Native Mitral Valve Infective Endocarditis
4.3.4.4.2 Role of Mitral Valve Repair in Infective Endocarditis
4.3.4.4.3 Pulmonary Homograft Endocarditis and Aortic Autograft Failure after Ross Procedure: Double Stentless Bioprosthesis Approach
4.3.4.5 MISCELLANEOUS
4.3.4.5.1 Six-Year Outcomes after Non-Resective Mitral Valve Repair with Artificial Chordae Using Removable Clips
4.3.4.5.2 An Alternative Intraoperative Method Based on Annular Circumference for the Decision-Making of Prophylactic Tricuspid Annuloplasty
4.3.4.5.3 Human Pulmonary Autograft Wall Stress at Systemic Pressures Prior to Remodelling After the Ross Procedure
4.3.4.5.4 Video 1 for Article: Human Pulmonary Autograft Wall Stress at Systemic Pressures Prior to Remodeling After the Ross Procedure
4.3.4.5.5 Video 2 for Article: Human Pulmonary Autograft Wall Stress at Systemic Pressures Prior to Remodeling After the Ross Procedure
4.3.4.6 CORRESPONDENCE
4.3.4.6.1 Letter to the Editor
4.3.5 Volume 23 Number 2 March 2014
4.3.5.1 AORTIC VALVE DISEASE
4.3.5.1.1 Reinforcement of the Pulmonary Artery Autograft with a Polyglactin and Polydioxanone Mesh in the Ross Operation: Experimental Study in Growing Lamb
4.3.5.1.2 Aortic Prosthesis-Patient Mismatch Strongly Affects Early Results of Double Valve Replacement
4.3.5.1.3 Aortic Valve Regurgitation Secondary to Ectopia and Atresia of the Left Main Coronary Artery
4.3.5.1.4 Does a Minimally Invasive Approach Increase the Incidence of Patient-Prosthesis Mismatch in Aortic Valve Replacement?
4.3.5.2 MITRAL VALVE DISEASE
4.3.5.2.1 Recurrent Native and Prosthetic Mitral Valve Thrombosis in Idiopathic Hypereosinophilic Syndrome
4.3.5.2.2 Hemodynamic Comparison of Mitral Valve Repair: Techniques for a Flail Anterior Leaflet
4.3.5.2.3 Contractile Reserve Induced with Dobutamine Echocardiography Predicts Outcome in Patients with Left Ventricular Dysfunction and Mitral Regurgitation
4.3.5.2.4 Spatial Relationship of Coronary Sinus-Great Cardiac Vein with Adjoining Anatomic Structures: A Key Element in Predicting the Success of Percutaneous Transvenous Mitral Annuloplasty
4.3.5.2.5 Mitral Annular Morphology in Mitral Valve Disease with Three-Dimensional Transesophageal Echocardiography
4.3.5.3 TRICUSPID VALVE DISEASE
4.3.5.3.1 Evidence of Tricuspid Valve Remodelling in Patients with Severe Mitral Regurgitation Independently of Degree of Functional Tricuspid Regurgitation: A Two- and Three-Dimensional Echocardiographic Study
4.3.5.3.2 Tricuspid Valve Replacement: The Effect of Gender on Operative Results
4.3.5.4 IATROGENIC DAMAGE
4.3.5.4.1 An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.2 Video 1 for Article: An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.3 Video 2 for Article: An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.4 Video 3 for Article: An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.5 Video 4 for Article: An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.6 Video 5 for Article: An Iatrogenic Atrioventricular Septal Defect that Developed Following Transfemoral TAVI
4.3.5.4.7 Ceftaroline for the Treatment of Prosthetic Valve Endocarditis due to Methicillin-Resistant Staphylococcus aureus
4.3.5.5 MISCELLANEOUS
4.3.5.5.1 Value of Serum Fibrinogen Levels in the Assessment of Mechanical Prosthetic Valve Thrombosis
4.3.5.5.2 Redo Valvular Surgery in Elderly Patients Aged >75 Years
4.3.5.5.3 Subclinical Rheumatic Heart Disease in an Eritrean High-School Population, Detected by Echocardiography
4.3.5.5.4 The Outcomes of Triple-Valve Surgery: Eleven Years' Experience From a Single Center
4.3.5.5.5 Function and Expression Differences Between Ergot and Non-Ergot Dopamine D2 Agonists on Heart Valve Interstitial Cells
4.3.5.5.6 Sutureless Perceval Aortic Valve in Comparison with the Stented Carpentier-Edwards Perimount Aortic Valve
4.3.6 Volume 23 Number 1 January 2014
4.3.6.1 AORTIC VALVE DISEASE
4.3.6.1.1 Absence of Left Ventricular Hypertrophy in Severe Isolated Aortic Stenosis and Preserved Left Ventricular Systolic Function
4.3.6.1.2 Comparison of Different Surgical Techniques in 112 Consecutive Patients with Aortic Root Operations: When Should the Valve be Spared?
4.3.6.1.3 Aortic Wall Thickness: An Independent Risk Factor for Aortic Dissection?
4.3.6.1.4 The Aortic Root: Simple as Possible, but not Simpler
4.3.6.1.5 Enlargement of the Aortic Annulus During Aortic Valve Replacement: A Review
4.3.6.1.6 Physicochemical and Micro-Tomographic Characterization of Inorganic Deposits Associated with Aortic Stenosis
4.3.6.2 MITRAL VALVE DISEASE
4.3.6.2.1 Mitral Valve Repair for Severe Organic Mitral Regurgitation in the Elderly
4.3.6.2.2 Systemic and Local Levels of Fetuin-A in Calcified Mitral Valves of Rheumatic Heart Disease
4.3.6.2.3 Long-Term Results of Mitral Valve Repair with Semi-Rigid Posterior Band Annuloplasty
4.3.6.2.4 Neurocognitive Deficit and Quality of Life after Mitral Valve Repair
4.3.6.2.5 Impact of Mitral Valve Geometry on Hemodynamic Efficacy of Surgical Repair in Secondary Mitral Regurgitation
4.3.6.2.6 Extended Posterior Leaflet Extension for Mitral Regurgitation in Giant Left Atrium
4.3.6.2.7 Intermediate Results of Transaortic Edge-to-Edge Repair of the Mitral Valve in Patients Undergoing Aortic Valve Replacement
4.3.6.3 DEVICE EVALUATION
4.3.6.3.1 Early Hemodynamic Performance of the BioValsalva Valved Conduit after Aortic Root Replacement
4.3.6.3.2 Long-Term Outcomes Following Medtronic Open Pivot™ Valved Conduit
4.3.6.3.3 Early and Mid-Term Functional and Hemodynamic Evaluation of the St. Jude Medical Regent 17 mm Aortic Valve Mechanical Prosthesis
4.3.6.3.4 In-Vitro Study of a Porcine Quadricuspid Aortic Valve
4.3.6.4 HOW TO DO IT
4.3.6.4.1 Bentall Operation in 375 Patients: Long-Term Results and Predictors of Death
4.3.6.4.2 Aortic Transection with Superior Biatrial Trans-Septal Approach for Triple Valve Re-Do Procedures
4.3.6.5 CASE REPORT
4.3.6.5.1 Simultaneous Transapical Paraprosthetic Leak Occlusion and Valve-in-Valve Implantation into a Degenerated Mitral Bioprosthesis
4.3.6.5.2 Dynamic Tricuspid Valve Stenosis Induced with a Pacemaker Lead: A Case Report
4.4 2013
4.4.1 Volume 22 Number 6 November 2013
4.4.1.1 AORTIC VALVE DISEASE
4.4.1.1.1 Delayed Coronary Ischemia after Transfemoral Aortic Valve Implantation
4.4.1.1.2 Operative Mortality and Morbidity after the Ross Procedure: A 26- Year Learning Curve
4.4.1.1.3 What are the Barriers to Training Residents in Aortic Root Surgery?
4.4.1.1.4 Release of Leukotriene B4, Transforming Growth Factor-β1 and Microparticles in Relation to Aortic Valve Calcification
4.4.1.1.5 Patient Gender Does Not Affect Outcome after Transcatheter Aortic Valve Implantation (TAVI)
4.4.1.1.6 Long-Term Hemodynamic Performance of ATS Valves in the Aortic Position: Impact on the Progression of Late Tricuspid Regurgitation
4.4.1.2 MITRAL VALVE DISEASE
4.4.1.2.1 Ventricular Energetics Early after Surgery for Chronic Mitral Regurgitation: Repair versus Replacement
4.4.1.3 DEVICE EVALUATION
4.4.1.3.1 Risk-Adjusted Survival after Tissue versus Mechanical Aortic Valve Replacement: A 23-Year Assessment
4.4.1.3.2 Short-Term Follow Up with the 3f Enable Aortic Bioprosthesis: Clinical and Echocardiographic Results
4.4.1.3.3 Combined Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation in Cardiogenic Shock
4.4.1.3.4 Ultrasound Phonocardiography for Detecting Thrombotic Formations on Bileaflet Mechanical Heart
4.4.1.3.5 Mechanical Valve Evaluation with Four-Dimensional Computed Tomography
4.4.1.4 INFECTIVE ENDOCARDITIS
4.4.1.4.1 Competent Mitral Valve after Annulus Ring Removal for Infective Endocarditis
4.4.1.4.2 Video for Article: Competent Mitral Valve after Annulus Ring Removal for Infective Endocarditis
4.4.1.4.3 16S rRNA Sequencing as a Diagnostic Tool in the Identification of Culture-Negative Endocarditis in Surgically Treated Patients
4.4.1.4.4 Contemporary Perioperative Results of Heart Valve Replacement in Dialysis Patients: Analysis of 1,616 Patients from the Japan Adult Cardiovascular Surgery Database
4.4.1.4.5 Eradication of Active Infective Endocarditis with Submitral Abscess Infiltrating to Annular Calcification
4.4.1.5 CASE REPORT
4.4.1.5.1 Left Ventricular Geometry and Systolic Function Improvement after Percutaneous Closure of Aortic Prosthetic Paravalvular Leak
4.4.1.5.2 Venous Intimal Hyperplasia with Occlusion of the Anastomosis between Saphenous Vein Graft and Carbo-Seal Dacron Tube after a Modified Bentall Procedure
4.4.1.5.3 Use of Tenecteplase in Recurrent Prosthetic Valve Thrombosis
4.4.1.5.4 Transcatheter Aortic Valve Implantation in Patients with Left Main Percutaneous Coronary Intervention
4.4.1.5.5 Quadricuspid Aortic Valve with Mild Aortic Regurgitation and Persistent Foramen Ovale: A Multimodality Imaging of Rare Concomitant Findings
4.4.1.5.6 Pseudoaneurysm of the Sinus of Valsalva with Coronary Artery Compression as the Primary Manifestation of Infective Endocarditis: A Case Report
4.4.1.5.7 Radiation-Associated Valvular Heart Disease
4.4.2 Volume 22 Number 5 September 2013
4.4.2.1 AORTIC VALVE DISEASE
4.4.2.1.1 Does the Body Mass Index Predict Mortality after Isolated Aortic Valve Replacement?
4.4.2.1.2 REDO Aortic Valve Replacement: The Sutureless Approach
4.4.2.1.3 TGF-β1-Induced MAPK Activation Promotes Collagen Synthesis, Nodule Formation, Redox Stress and Cellular Senescence in Porcine Aortic Valve Interstitial Cells
4.4.2.1.4 Side-Specific Characterization of Aortic Valve Endothelial Cell Adhesion Molecules Under Cyclic Strain
4.4.2.1.5 Myeloperoxidase and Progression of Aortic Valve Stenosis in Patients Undergoing Hemodialysis
4.4.2.1.6 Patient with a Starr-Edwards Prosthesis in the Aortic Position for 40 Years
4.4.2.2 MITRAL VALVE DISEASE
4.4.2.2.1 Effect of Mitral Valve Repair versus Replacement on Left Ventricular Rotational Deformation: A Study with Speckle Tracking Echocardiography
4.4.2.2.2 Should an Inoue Balloon Larger than Suggested by Guidelines be Used for Percutaneous Balloon Mitral Valvuloplasty?
4.4.2.2.3 Minimally Invasive Mitral Valve Reconstruction on the Fibrillating Heart for High-Risk Patients
4.4.2.2.4 Is There an Alternative Explanation to Post-Myocardial Infarction Emergence of Mitral Regurgitation? A CMR-LGE Observational Study
4.4.2.2.5 Takotsubo Cardiomyopathy after Minimally Invasive Mitral Valve Surgery: Clinical Case and Review
4.4.2.2.6 Long-Term Results of Surgical Correction for Mitral Paravalvular Leak: Repair versus Re-Replacement
4.4.2.3 TRANSCATHETER VALVE IMPLANTATION
4.4.2.3.1 Hemodynamics in the Valsalva Sinuses after Transcatheter Aortic Valve Implantation (TAVI)
4.4.2.3.2 Transcatheter Implantation of a CoreValve Aortic Prosthesis in a Patient with a Ball-Cage Mechanical Mitral Valve
4.4.2.3.3 Delayed Aortic Dissection after Transcatheter Aortic Valve Implantation
4.4.2.4 INFECTIVE ENDOCARDITIS
4.4.2.4.1 Long-Term Clinical Outcomes and Predictors of Survival after Prosthetic Valve Endocarditis Surgery
4.4.2.4.2 Stroke and Thrombus Formation Appending to the MitraClip™: What is the Appropriate Anticoagulation Regimen?
4.4.2.4.3 Postoperative Warfarin Following Mitral Valve Repair or Bioprosthetic Valve Replacement
4.4.2.4.4 Techniques of Autologous Pericardial Leaflet Replacement for Bicuspid Aortic Valve Endocarditis
4.4.2.5 MISCELLANEOUS
4.4.2.5.1 An Old Mitral Homograft in the Tricuspid Position
4.4.2.5.2 Outcomes of Minimally Invasive Triple Valve Surgery Performed Via a Right Anterior Thoracotomy Approach
4.4.2.5.3 Resistance to Secondary Thrombosis of the On-X Mitral Prosthesis
4.4.2.5.4 The Significance of Prosthesis Type on Survival Following Valve Replacement in Dialysis Patients
4.4.2.5.5 Surgical-Transcatheter Approach for Endocarditis of a Calcified Aortic Homograft
4.4.2.5.6 Right Ventricular Reduction for Repair of Functional Tricuspid Valve Regurgitation: One-Year Follow Up
4.4.3 Volume 22 Number 4 July 2013
4.4.3.1 AORTIC VALVE DISEASE
4.4.3.1.1 Comparison Between Transcatheter and Surgical Aortic Valve Replacement: A Single-Center Experience
4.4.3.1.2 Advanced Age Per Se Should not be an Exclusion Criterion for Minimally Invasive Aortic Valve Replacement
4.4.3.1.3 Percutaneous Temporary Aortic Valve: A Proof-of-Concept Animal Model
4.4.3.1.4 Optimal Results of Aortic Valve Replacement with Small Mechanical Valves (<19 mm)
4.4.3.1.5 Relationship between Morphologic Features of Myocardial Tissue and Left Ventricular Function in Patients with Aortic Valve Disease and Left Ventricular Hypertrophy
4.4.3.1.6 Aortic Valve Leaflet Glycosaminoglycans Composition and Modification in Severe Chronic Valve Regurgitation
4.4.3.1.7 Evaluation of Cardiac Valvular Regurgitant Lesions by Cardiac MRI Sequences: Comparison of a Four-Valve Semi-Quantitative versus Quantitative Approach
4.4.3.1.8 Aortic Root Replacement with a Stented Bioprosthetic Valved Conduit: Mid-Term Results
4.4.3.1.9 Impact of Postoperative Cusp Configuration on Mid-Term Durability after Aortic Root Reimplantation
4.4.3.1.10 Predictive Value of Five Risk Scores to Predict Outcomes after Aortic Valve Replacement in Octogenarians
4.4.3.2 MITRAL VALVE DISEASE
4.4.3.2.1 Surgical Relocation of the Papillary Muscles in Functional Ischemic Mitral Regurgitation: What are the Forces of the Relocation Stitches Acting on the Myocardium?
4.4.3.2.2 Mitral Valve Resistance Correlates More Closely with Left Atrial Deformation than with Conventional Indices of Rheumatic Mitral Stenosis
4.4.3.2.3 Mitral Subvalvular Plasty for Chronic Ischemic Mitral Regurgitation: A Preliminary Experimental Model
4.4.3.2.4 Three-Dimensional Echocardiographic Assessment Before and After Percutaneous Transvenous Mitral Commissurotomy in Patients with Rheumatic Mitral Stenosis
4.4.3.2.5 Impact of Rheumatic Mitral Stenosis on Aortic Elastic Properties
4.4.3.2.6 Symmetrical Papillary Muscle Approximation for Functional Mitral Regurgitation with Idiopathic Dilated Cardiomyopathy
4.4.3.3 INFECTIVE ENDOCARDITIS
4.4.3.3.1 Fresh Autologous Pericardium for Leaflet Perforation Repair in Mitral Valve Infective Endocarditis
4.4.3.3.2 Comparison Between Early and Late Prosthetic Valve Endocarditis: Clinical Characteristics and Outcomes
4.4.3.3.3 Technique to Treat Extensive Abscesses in Double Valve Replacement for Prosthetic Valve Endocarditis
4.4.3.3.4 Surgical Management of Tricuspid Valve Endocarditis in Systemically Infected Patients
4.4.3.4 MISCELLANEOUS
4.4.3.4.1 Valvular Calcification, Inflammation, and Mortality in Dialysis Patients
4.4.3.4.2 Reoperation for Non-Structural Valvular Dysfunction Caused by Pannus Ingrowth in Aortic Valve Prosthesis
4.4.3.5 CASE REPORT
4.4.3.5.1 Diagnosis and Surgical Management of Subaortic Stenosis and Mitral Valve Systolic Anterior Motion
4.4.3.5.2 Mechanical Heart Valve Thrombosis in Pregnancy
4.4.3.6 CORRESPONDENCE
4.4.3.6.1 Renal Cell Carcinoma with Extensive Cavoatrial Involvement
4.4.4 Volume 22 Number 3 May 2013
4.4.4.1 AORTIC VALVE DISEASE
4.4.4.1.1 Health-Related Quality of Life Following Isolated Aortic Valve Surgery: Is Earlier Intervention Better?
4.4.4.1.2 Prevention and Management of Potential Adverse Events During Transapical Aortic Valve Replacement
4.4.4.1.3 Clinical Factors Associated with Classical Symptoms of Aortic Valve Stenosis
4.4.4.1.4 Upper ‘J’ Ministernotomy versus Full Sternotomy: An Easier Approach for Aortic Valve Reoperation
4.4.4.1.5 Logistic EuroSCORE I Risk Analysis in Aortic Valve Reoperations after Bioprosthetic Replacement
4.4.4.1.6 Incidence and Impact of Prosthesis-Patient Mismatch after Transcatheter Aortic Valve Implantation
4.4.4.1.7 Sclerostin as a Potential Novel Biomarker for Aortic Valve Calcification: An In-Vivo and Ex-Vivo Study
4.4.4.2 MITRAL VALVE DISEASE
4.4.4.2.1 Mid-Term Echocardiographic Comparison of Chordal Preservation Method of Mitral Valve Replacement in Patients with Mitral Stenosis
4.4.4.2.2 Mitral Valve Repair versus Replacement in Patients with Rheumatic Heart Disease
4.4.4.2.3 Investigation of the Suitability of Decellularized Porcine Pericardium in Mitral Valve Reconstruction
4.4.4.2.4 Long-Term Outcomes of Early Surgery for Asymptomatic Severe Chronic Mitral Regurgitation
4.4.4.3 DEVICE EVALUATION
4.4.4.3.1 Textile Heart Valve Prosthesis: From Fabric Design Criteria to Early In-Vivo Performances
4.4.4.3.2 Porcine Models of Non-Bacterial Thrombotic Endocarditis (NBTE) and Infective Endocarditis (IE) Caused by Staphylococcus aureus: A Preliminary Study
4.4.4.3.3 True External Diameter Better Predicts Hemodynamic Performance of Bioprosthetic Aortic Valves than the Manufacturers’ Stated Size
4.4.4.3.4 Gal-Knockout Bioprostheses Exhibit Less Immune Stimulation Compared to Standard Biological Heart Valves
4.4.4.4 MISCELLANEOUS
4.4.4.4.1 Presence of Valvular Calcification Predicts the Response to Cinacalcet: Data from the ADVANCE Study
4.4.4.4.2 Circulating Plasma and Platelet 5-Hydroxytryptamine in Carcinoid Heart Disease: A Pilot Study
4.4.4.4.3 Prooxidant-Antioxidant Balance and Cardiac Function in Patients with Cardiovascular Disease Following Cardiac Surgery
4.4.4.4.4 Prognostic Variables for Clinical Outcomes in Valvular Heart Disease Patients with Moderate to Severe Secondary Tricuspid Regurgitation
4.4.4.5 CASE REPORT
4.4.4.5.1 Pulmonary Valve-Sparing Technique in Patient with Tetralogy of Fallot and Anomalous Coronary Artery Crossing the Infundibulum
4.4.4.5.2 Corynebacterium striatum: An Emerging Nosocomial Drug-Resistant Endocardial Pathogen
4.4.4.5.3 Reoperative Reimplantation Procedure after Previous Remodeling in a Patient with Marfan Syndrome
4.4.4.5.4 Successful Transcatheter Valve-in-Valve Implantation in a Small Deteriorated Aortic Valve Bioprosthesis
4.4.4.5.5 Sutureless Medtronic 3f Enable® Aortic Valve Replacement in a Heavily Calcified Aortic Root
4.4.4.5.6 Congenital Discrete Subaortic Stenosis in Pregnancy: Case Report and Literature Review
4.4.4.5.7 Biodegradable Annuloplasty Ring Two Years after Implantation: First Histological Demonstration in Human Mitral Annulus
4.4.5 Volume 22 Number 2 March
4.4.5.1 AORTIC VALVE DISEASE
4.4.5.1.1 NOTCH1 Genetic Variants in Patients with Tricuspid Calcific Aortic Valve Stenosis
4.4.5.1.2 A Pilot Project of Familial Screening in Patients with Bicuspid Aortic Valve Disease
4.4.5.1.3 Comparison of Transesophageal Echocardiographic Analysis and Circulating Biomarker Expression Profile in Calcific Aortic Valve Disease
4.4.5.1.4 Circulating Collagen Metabolites, Myocardial Fibrosis and Heart Failure in Aortic Valve Stenosis
4.4.5.1.5 Impact of Concomitant Coronary Artery Bypass Grafting on In-Hospital Outcome in Octogenarians Undergoing Aortic Valve Replacement
4.4.5.1.6 Impact of Smoking Status on Early and Late Outcomes after Isolated Aortic Valve Replacement Surgery
4.4.5.1.7 Mid-Term Echocardiographic Progression of Patients with Moderate Aortic Regurgitation: Implications for Aortic Valve Surgery
4.4.5.1.8 Pulmonary Artery Conduit In Vivo Dimensional Requirements in a Growing Ovine Model: Comparisons with the Ascending Aorta
4.4.5.1.9 Outcomes of Transcatheter Aortic Valve Implantation Compared to Surgical Aortic Valve Replacement Following Previous Surgery
4.4.5.2 DEVICE EVALUATION
4.4.5.2.1 Outcomes of Pericardial Bovine Xenografts for Right Ventricular Outflow Tract Reconstruction in Children and Young Adults
4.4.5.2.2 Short-Term and Mid-Term Results with the Sorin Freedom Solo Aortic Valve
4.4.5.2.3 Anti-Alpha-Gal Antibody Response Following Xenogeneic Heart Valve Implantation in Adults
4.4.5.2.4 Minimally Invasive Aortic Valve Replacement with Self-Anchoring Perceval Valve
4.4.5.2.5 Computed Tomography Image Processing to Detect the Real Mechanism of Bioprosthesis Failure: Implication for Valve-In-Valve Implantation
4.4.5.3 MISCELLANEOUS
4.4.5.3.1 Evaluation of Nutritional Screening Tools among Patients Scheduled for Heart Valve Surgery
4.4.5.3.2 Retrospective Evaluation of Infective Endocarditis over Ten Years in Taiwan
4.4.5.4 CASE REPORT
4.4.5.4.1 Large Pseudoaneurysm of the Sinus of Valsalva after Surgery for Aortic Valve Endocarditis
4.4.5.4.2 Late Severe Left Ventricular Dysfunction after Successful Transapical Aortic Valve Implantation: A Cause for Concern
4.4.5.4.3 Transcatheter Aortic Valve Implantation and Four-Year Follow Up in a 99-Year-Old Patient
4.4.5.4.4 Double-Balloon Valvuloplasty of Calcified Bioprosthetic Pulmonary Valve Twenty-Three Years after Implantation
4.4.6 Volume 22 Number 1 January 2013
4.4.6.1 Editorial: The 7th Biennial Meeting of the Society for Heart Valve Disease
4.4.6.2 MITRAL VALVE DISEASE
4.4.6.2.1 Determinants of Left Atrial Reverse Remodeling after Valve Surgery for Degenerative Mitral Regurgitation
4.4.6.2.2 Minimally Invasive Transaortic Edge-to-Edge Repair of the Mitral Valve
4.4.6.2.3 Mitral Valve Procedure Selection and Outcomes in Patients with Rheumatoid Arthritis
4.4.6.2.4 Tissue Doppler-Derived Isovolumic Acceleration Parameters in Organic Mitral Regurgitation
4.4.6.2.5 Mitral Valve Mechanics Following Posterior Leaflet Patch Augmentation
4.4.6.2.6 Antiphospholipid Antibody-Associated Non-Infective Mitral Valve Endocarditis Successfully Treated with Medical Therapy
4.4.6.2.7 Posterior Leaflet P2-P1 Transposition for Mitral Repair in a Case of Infective Endocarditis
4.4.6.3 AORTIC VALVE DISEASE
4.4.6.3.1 Etiology Impacts Survival in Patients with Severe Aortic Regurgitation: Results from a Cohort of 756 Patients
4.4.6.3.2 Outcomes of Reoperative Aortic Valve Replacement via Right Mini-Thoracotomy versus Median Sternotomy
4.4.6.3.3 Impact of Patient-Prosthesis Mismatch in the Aortic Position: Twenty-Year Experience with Korean Patients
4.4.6.3.4 Silent Aortic Regurgitation in Systemic Hypertension
4.4.6.3.5 Two-Year Mortality after Transcatheter Aortic Valve Implantation Versus Medical Therapy for High-Surgical Risk or Inoperable Aortic Stenosis Patients
4.4.6.3.6 Cerebral Embolization during Percutaneous Valve Implantation does not Occur during Balloon Inflation Valvuloplasty: Prospective Diffusion-Weighted Brain MRI Study
4.4.6.3.7 Transaortic Transcatheter Aortic Valve Implantation for Failed Surgical Aortic Valve Replacement due to ëPorcelain Aortaí
4.4.6.3.8 Transcatheter Aortic Valve Implantation with a CoreValveô Bioprosthesis in a 57-Year-Old Man
4.4.6.4 MISCELLANEOUS
4.4.6.4.1 Mortality Risk Model for Heart Valve Surgery in China
4.4.6.4.2 Adequate Intensity of Warfarin Therapy for Korean Patients with Mechanical Cardiac Valves
4.4.6.4.3 Valve Surgery for Infective Endocarditis is Associated with High Hospital Charges
4.4.6.4.4 Regulatory T-Cell Deficiency in Rheumatic Heart Disease: A Preliminary Observational Study
4.4.6.4.5 Recurrent Prosthetic Valve Endocarditis with Aortic-Ventricular Disruption: A Surgical Challenge
4.4.6.4.6 GPIb VNTR C/C Genotype May Predict Embolic Events in Infective Endocarditis
4.5 2012
4.5.1 Volume 21 Number 6 November 2012
4.5.1.1 MITRAL VALVE DISEASE
4.5.1.1.1 Current Trends in Mitral Valve Repair Techniques in North America
4.5.1.1.2 Changes in Mitral Annular Geometry after Aortic Valve Replacement: A Three-Dimensional Transesophageal Echocardiographic Study
4.5.1.1.3 Intra-Atrial Placement of a Mitral Prosthesis in Patients with Severe Mitral Annular Calcification
4.5.1.2 AORTIC VALVE DISEASE
4.5.1.2.1 Echocardiographic Surveillance of Aortic Valve Stenosis: Towards a Standardized Approach
4.5.1.2.2 Spontaneous Intracranial Hypotension in Patients with Bicuspid Aortic Valve
4.5.1.2.3 Aortic Valve Hydrodynamics: Considerations on the Absence of Sinuses of Valsalva
4.5.1.2.4 The Impact of Balloon Aortic Valvuloplasty on Aortic Regurgitation in Patients with Severe Aortic Stenosis
4.5.1.2.5 Aortic Cross-Clamp Time, New Prostheses, and Outcome in Aortic Valve Replacement
4.5.1.2.6 Repair of Quadricuspid Aortic Valve Associated with Ascending Aorta Dilatation
4.5.1.3 TRICUSPID VALVE DISEASE
4.5.1.3.1 Pulmonary Arterial Pressure and Right Ventricular Dilatation Independently Determine Tricuspid Valve Insufficiency Severity in Pre-Capillary Pulmonary Hypertension
4.5.1.3.2 Robot-Assisted Repair of Tricuspid Leaflet Prolapse Using Standard Valvuloplasty Techniques
4.5.1.4 DEVICE EVALUATION
4.5.1.4.1 Mid-Term Follow Up of a Novel Bioprosthesis in Aortic Valve Surgery
4.5.1.4.2 Sutureless Aortic Valve Replacement: Catheter-Based Transapical versus Direct Transaortic Implantation
4.5.1.4.3 Elliptical Shape of a SAPIEN XT Prosthesis Deployed in a Patient with Bicuspid Aortic Valve Stenosis
4.5.1.5 MISCELLANEOUS
4.5.1.5.1 The Impact of Pulmonary Hypertension on Outcomes of Patients with Low Left Ventricular Ejection Fraction: A Propensity Analysis
4.5.1.5.2 Surgical Treatment of Infective Endocarditis in Patients Undergoing Chronic Hemodialysis
4.5.1.5.3 A Case of Starr-Edwards Valve Thrombosis in Pregnancy
4.5.1.5.4 Left Ventricular Mass Regression is Independent of Gradient Drop and Effective Orifice Area after Aortic Valve Replacement with a Porcine Bioprosthesis
4.5.2 Volume 21 Number 5 September 2012
4.5.2.1 MITRAL VALVE DISEASE
4.5.2.1.1 Factors Predicting Emergency Surgery in Severe Mitral Regurgitation Following Mitral Balloon Valvotomy
4.5.2.1.2 Mitral Annuloplasty with IMR ETlogix® Ring for Ischemic Mitral Regurgitation and Left Ventricular Dysfunction
4.5.2.1.3 The Impact of Percutaneous Coronary Intervention on Ischemic Mitral Regurgitation
4.5.2.1.4 Serum 25-Hydroxyvitamin D Levels are Correlated with Mitral Valve Calcification Score in Patients with Rheumatic Mitral Stenosis
4.5.2.2 AORTIC VALVE DISEASE
4.5.2.2.1 Aortic Valve Replacement in Asymptomatic and Symptomatic Patients with Preserved Left Ventricular Ejection Fraction
4.5.2.2.2 Reduction Aortoplasty: Safe and Durable Treatment for Borderline Dilatation in Selected Patients
4.5.2.2.3 Aortic Annulus Diameter and Valve Design Each Determine the Valve Size Implanted
4.5.2.2.4 One-Year Observation of Inflammatory Markers in Patients with Aortic Valve Stenosis who Expressed High or Low Chlamydia pneumoniae Antibody Titers
4.5.2.2.5 Abnormal Left Ventricular Mechanics in isolated Bicuspid Aortic Valve Disease may be independent of aortic distensibility: 2D Strain Imaging Study
4.5.2.2.6 Outcomes after Valve-Preserving Root Surgery for Patients with Marfan Syndrome
4.5.2.2.7 Effect of Concomitant Asymmetric Septal Hypertrophy when Assessing the Severity of Aortic Valve Stenosis: An In-Vitro Study
4.5.2.3 THROMBOSIS, EMBOLISM AND BLEEDING
4.5.2.3.1 The Combined Effects of Clinical Factors and CYP2C9 and VKORC1 Gene Polymorphisms on Initiating Warfarin Treatment in Patients after Cardiac Valve Surgery
4.5.2.3.2 Management of Heparin-Induced Thrombocytopenia during Thrombolytic Therapy for Prosthetic Valve Thrombosis
4.5.2.4 TRIPLE VALVE SURGERY
4.5.2.4.1 Advanced Age: A Contraindication for Triple-Valve Surgery?
4.5.2.4.2 Triple Valve Repair in Children with Rheumatic Heart Disease: Long-Term Experience
4.5.2.5 REPLACEMENT DEVICES
4.5.2.5.1 Reduction in Platelet Count after Aortic Valve Replacement: Comparison of Three Bioprostheses
4.5.2.5.2 Hemodynamic Characteristics of Edwards Sapien Aortic Valve Prosthesis Assessed with Transesophageal Echocardiography
4.5.2.5.3 Trans-Apical versus Surgical Implantation of Autologous Ovine Tissue-Engineered Heart Valves
4.5.2.6 CASE REPORTS
4.5.2.6.1 Favorable Evolution of a 43-Year-Old Starr-Edwards Valve in the Tricuspid Position
4.5.2.6.2 Bartonella henselae Endocarditis of Percutaneously Implanted Pulmonary Valve
4.5.2.7 LETTER TO THE EDITOR
4.5.2.7.1 Re: Alfieri O, DeBonis MJ. Invited Comment. J Heart Valve Dis 2011;20:415-416
4.5.2.8 IMAGES OF THE MONTH
4.5.2.8.1 A Blood Cyst on the Anterior Mitral Valve Leaflet Complicated by Cerebrovascular Stroke
4.5.2.8.2 A Case of Angina from a Pseudoaneurysm after Aortic Root Replacement
4.5.3 Volume 21 Number 4 July 2012
4.5.3.1 MITRAL VALVE DISEASE
4.5.3.1.1 Mitral Valve Prolapse with Left Atrial Enlargement Out of Proportion to Mitral Regurgitation
4.5.3.1.2 Animal Models of Mitral Regurgitation Induced by Mitral Valve Chordae Tendineae Rupture
4.5.3.1.3 Rheumatic Mitral Repair Versus Replacement in a Threshold Country: The Impact of Commissural Fusion
4.5.3.1.4 Structural Changes of Rat Mitral Valve Chordae Tendineae During Postnatal Development
4.5.3.1.5 Recurrent Mitral Regurgitation Due to Ruptured Artificial Chordae: Case Report and Review of the Literature
4.5.3.1.6 Repair of Disrupted Mitral Annuloplasty Following Blunt Chest Trauma
4.5.3.1.7 Undersized Annuloplasty for Functional Mitral Regurgitation: Is it Responsible for Clinically Relevant Mitral Stenosis During Exercise?
4.5.3.2 AORTIC VALVE DISEASE
4.5.3.2.1 Progression of Aortic Valve Stenosis in Adults: A Systematic Review
4.5.3.2.2 Rosuvastatin Slows the Development of Diastolic Dysfunction in Calcific Aortic Stenosis
4.5.3.2.3 Editorial Aldosterone Antagonists and Chronic Aortic Regurgitation: Promising But Not Quite Ready for Prime Time
4.5.3.2.4 Editorial Potentially Modifiable Biological Targets in Aortic Regurgitation
4.5.3.2.5 Effects of Spironolactone Treatment on an Experimental Model of Chronic Aortic Valve Regurgitation
4.5.3.2.6 Urgent Aortic Valve Replacement in Octogenarians: Does an ‘Urgent’ Status Increase Morbidity and Mortality?
4.5.3.2.7 An Automated Coring and Apical Connector Insertion Device Facilitates Aortic Valve Bypass (Apicoaortic Conduit) Surgery: Preclinical Experience in a Chronic Ovine Model
4.5.3.3 MISCELLANEOUS
4.5.3.3.1 Left Atrial Dissection after Mitral Valve Replacement can Mimic Periprosthetic Regurgitation
4.5.3.3.2 Aortopulmonary Fistula after a Modified Bentall Procedure
4.5.3.3.3 Lipid Insudation as a Cause of Structural Failure of a Stentless Pericardial Bioprosthesis
4.5.3.3.4 A Novel Technique for Quantifying Mouse Heart Valve Leaflet Stiffness with Atomic Force Microscopy
4.5.3.3.5 Evolution of the Z-Score in Size-Reduced Bicuspid Homografts
4.5.3.3.6 Regional Mechanical Properties of Human Pulmonary Root Used for the Ross Operation
4.5.3.3.7 Bioactive Porcine Matrices in Heart Valve Tissue Engineering
4.5.3.3.8 Individualized Quantified Tricuspid Valve Annuloplasty for Treating Ebstein Anomaly
4.5.3.4 LETTER TO THE EDITOR
4.5.3.4.1 Heart Rupture and Tamponade with a Short Review of Cause of Death in Ebstein Anomaly
4.5.4 Volume 21 Number 3 May 2012
4.5.4.1 EDITORIAL
4.5.4.1.1 Editorial: The Way Ahead
4.5.4.2 MITRAL VALVE DISEASE
4.5.4.2.1 Pharmacotherapy in the Treatment of Mitral Regurgitation: A Systematic Review
4.5.4.2.2 Strength Comparison of Mitral Annuloplasty Ring and Suturing Combinations: An In-Vitro Study
4.5.4.2.3 Etiologic Spectrum and Clinical Features of Mitral Regurgitation in a Spanish Population
4.5.4.2.4 Mitral Annular Geometry in Normal and Myxomatous Mitral Valves: Three-Dimensional Transesophageal Echocardiographic Quantification
4.5.4.3 AORTIC VALVE DISEASE
4.5.4.3.1 Editorial: Aortic Stenosis and Perioperative Risk: The Other Obstructive Defect
4.5.4.3.2 Risk of Aortic Valve Replacement in Patients with Aortic Stenosis and Chronic Obstructive Pulmonary Disease
4.5.4.3.3 Correlation of Calcification on Excised Aortic Valves by Micro-Computed Tomography with Severity of Aortic Stenosis
4.5.4.3.4 Slow Rate of Progression of Grade 1 and 2+ Aortic Regurgitation
4.5.4.3.5 Natriuretic Peptides and Long-Term Mortality in Patients with Severe Aortic Stenosis
4.5.4.3.6 The Effect of Angiotensin-Converting Enzyme Inhibitors and Statins on the Progression of Aortic Sclerosis and Mortality
4.5.4.3.7 Transapical Valve-in-Valve Implantation for Regurgitant Stented Aortic Bioprostheses
4.5.4.3.8 Atrial Fibrillation Ablation in Patients Undergoing Aortic Valve Replacement
4.5.4.3.9 Results of Aortic Valve Replacement with the Supra-Annular Sorin Bicarbon Overline Prosthesis
4.5.4.3.10 Delayed Left Ventricle-to-Right Atrial Fistula Following Aortic Valve Replacement
4.5.4.4 TRICUSPID VALVE DISEASE
4.5.4.4.1 Editorial: How are the Leaflets of the Tricuspid Valve Anchored at the Right Atrioventricular Junction?
4.5.4.4.2 Histologic Analysis of the Right Atrioventricular Junction in the Adult Human Heart
4.5.4.4.3 Renal Cell Carcinoma with Invasion of the Tricuspid Valve Apparatus
4.5.4.5 MISCELLANEOUS
4.5.4.5.1 Immunohistochemical Detection of uPA, PAI-1, and α-SMA in Aneurysms of Patients with Perimembranous Ventricular Septal Defect
4.5.4.5.2 Calcified Left Ventricular Endomyocardial Fibrosis
4.5.4.5.3 Elimination of α-Gal Xenoreactive Epitope: α-Galactosidase Treatment of Porcine Heart Valves
4.5.4.5.4 Asymptomatic Pediatric Pulmonic Valve Myxoma Involving the Right Ventricular Outflow Tract: A Case Report and Review of the Literature
4.5.4.5.5 Postoperative Cardiac Homograft Involvement in Erdheim-Chester Disease
4.5.4.6 LETTERS TO THE EDITOR
4.5.4.6.1 Von Willebrand’s Disease Following Aortic Valve Replacement
4.5.4.6.2 Right-Heart Failure and Hypotension after Arteriovenous Graft Placement in a Patient with Idiopathic Tricuspid Annular Dilatation
4.5.4.6.3 Dobutamine Stress-Induced Stroke in a Patient with Mechanical Mitral Prosthesis Despite Normal Function
4.5.4.7 IMAGES OF THE MONTH
4.5.4.7.1 Circumflex Artery Percutaneous Revascularization after Minimally Invasive Double Valve Annuloplasty and Left Atrium Ablation
4.5.4.7.2 Isolated Cleft of the Tricuspid Valve: A Variety of Tricuspid Regurgitation
4.5.4.7.3 Successful Repair for Isolated Cleft Mitral Valve Diagnosed by Three-Dimensional Transesophageal Echocardiography
4.5.5 Volume 21 Number 2 March 2012
4.5.5.1 AORTIC VALVE DISEASE
4.5.5.1.1 Computational Finite Element Analyses to Optimize Graft Sizing During Aortic Valve-Sparing Procedure
4.5.5.1.2 Conventional Aortic Valve Replacement Remains a Safe Option in Patients Aged ≥70 Years: A 20-Year Experience
4.5.5.1.3 Editorial Critical Aortic Stenosis: One More Vulnerable Group for Patient-Prosthesis Mismatch
4.5.5.1.4 Impact of Aortic Stenosis Severity and its Interaction with Prosthesis-Patient Mismatch on Operative Mortality Following Aortic Valve Replacement
4.5.5.1.5 Sutureless Aortic Valve Replacement Through a Right Minithoracotomy
4.5.5.1.6 An Acute Animal Model of Aortic Stenosis: Initial Attempts at Leaflet Modification
4.5.5.1.7 Valve-Sparing Aortic Root Replacement for Patients with a Fontan Circulation
4.5.5.1.8 Aortic Root Distensibility after Subcoronary Stentless Valve Implantation
4.5.5.1.9 Aortic Elastic Properties and Left Ventricular Diastolic Function in Patients with Isolated Bicuspid Aortic Valve
4.5.5.1.10 Mid-Term Results of Different Aortic Valve-Sparing Procedures in Marfan Syndrome
4.5.5.2 MITRAL VALVE DISEASE
4.5.5.2.1 Hemodynamic Assessment of Mitral Stenosis: Mitral Valve Resistance as an Echocardiographic Index
4.5.5.2.2 Percutaneous Closure of Mitral Paravalvular Leaks: A Systematic Review and Meta-Analysis
4.5.5.2.3 Persistence of Mitral Regurgitation Following Ring Annuloplasty: Is the Papillary Muscle Outside or Inside the Ring?
4.5.5.2.4 The Effects of Dynamic Saddle Annulus and Leaflet Length on Transmitral Flow Pattern and Leaflet Stress of a Bileaflet Bioprosthetic Mitral Valve
4.5.5.3 MISCELLANEOUS
4.5.5.3.1 Valvular Heart Diseases in the Developing World: Developmental Biology Takes Center Stage
4.5.5.3.2 The Pathology of TRI-Tech Valve Leaflet Escape
4.5.5.3.3 An Ovine Model of Pulmonary Insufficiency and Right Ventricular Outflow Tract Dilatation
4.5.5.3.4 The Role of the Sewing Ring in Tissue Healing: A Pathologic Study of Explanted Mechanical Heart Valves
4.5.5.3.5 Pasteurella multocida Endocarditis
4.5.5.4 HOW TO DO IT
4.5.5.4.1 An Interrupted Suture Technique for Ascending Aortic Replacement Concomitant to Aortic Valve Repair
4.5.5.5 CASE REPORTS
4.5.5.5.1 Double Freestyle Valve Replacement in a Patient with a Prior Ross Procedure
4.5.5.5.2 Tricuspid Valvar Regurgitation in Congenital Absence of the Pericardium
4.5.5.6 LETTERS TO THE EDITOR
4.5.5.6.1 Mitral Regurgitation as a Late Complication of Stroke Prevention by the WATCHMAN-Device
4.5.5.6.2 Lambl’s Excrescence: Recapitulation of a Human Phenotype in a Mouse
4.5.6 Volume 21 Number 1 January 2012
4.5.6.1 REVIEW ARTICLE
4.5.6.1.1 The Case for a Specialist Multidisciplinary Valve Clinic
4.5.6.2 AORTIC VALVE DISEASE
4.5.6.2.1 Aortic Valve Re-Replacement after Bentall Procedure with a Biological Valved Conduit in a Sheep Model
4.5.6.2.2 Regional Variation in Prosthesis Choice for Aortic Valve Replacement in Older Patients
4.5.6.2.3 Complementary Assessment of Aortic Bioprosthetic Dysfunction Using Cardiac Magnetic Resonance Imaging and Computed Tomography
4.5.6.2.4 Tezosentan Inhibits Uptake of Proinflammatory Endothelin-1 in Stenotic Aortic Valves
4.5.6.2.5 Does Gender Affect the Rates of Abnormal Exercise Stress Echocardiography in Patients with Asymptomatic Severe Aortic Stenosis?
4.5.6.3 MITRAL VALVE DISEASE
4.5.6.3.1 New Echocardiography-Based Classification of Mitral Valve Pathology: Relevance to Surgical Valve Repair
4.5.6.3.2 Impact of Hospital Annual Mitral Procedural Volume on Mitral Valve Repair Rates and Mortality
4.5.6.3.3 Geographic Variation in Procedure Selection and Hospital Mortality in Mitral Valve Surgery
4.5.6.3.4 Risk of Reoperation for Mitral Bioprosthesis Dysfunction
4.5.6.3.5 Early Surgery for Asymptomatic Mitral Regurgitation: Importance of Atrial Fibrillation
4.5.6.3.6 Assessment of a Novel Stentless Mitral Valve Using a Pulsatile Mitral Valve Simulator
4.5.6.4 ANTICOAGULATION
4.5.6.4.1 Editorial Patterns of Anticoagulation Following Bioprosthetic Valve Implantation: Observations from ANSWER
4.5.6.4.2 Patterns of Anticoagulation Following Bioprosthetic Valve Implantation: Observations from ANSWER
4.5.6.4.3 Twenty Years’ Single-Center Experience with Mechanical Heart Valves: A Critical Review of Anticoagulation Policy
4.5.6.5 DEVICE EVALUATION
4.5.6.5.1 Diastolic Properties of the Sorin Solo, ATS 3F, Edwards Prima Plus and Medtronic Freestyle Stentless Valves: An Independent In-Vitro Comparison
4.5.6.5.2 Editorial Predicting the Occurrence of Valve Prosthesis-Patient Mismatch: The Need for More Data
4.5.6.5.3 Manufacturer-Provided Effective Orifice Area Index Charts and the Prevention of Prosthesis-Patient Mismatch
4.5.6.5.4 Carpentier-Edwards Magna Ease versus Magna Valves: A Comparison of In-Vitro Valve Hydrodynamic Performance
4.5.6.6 MISCELLANEOUS
4.5.6.6.1 Infective Endocarditis in a Tertiary Referral Hospital: Long-Term Follow Up
4.5.6.6.2 Heart Valve Engineering: Decellularized Aortic Homograft Seeded with Human Cardiac Stromal Cells
4.5.6.7 CASE REPORT
4.5.6.7.1 Left Coronary Ostium Isolation and Aortic Valve Dysplasia in a Young Boy: A Case Report
4.5.6.8 LETTERS TO THE EDITOR
4.5.6.8.1 Valve Leaflet Reconstruction in Pediatrics with Extracellular Matrix Patch
4.5.6.8.2 First Documented Surgical Case of Human Aortic Valve Endocarditis Caused by Pasteurella haemolytica
4.5.6.8.3 Events in Aortic Stenosis Patients with Diabetes
4.6 2011
4.6.1 Volume 20 Number 6 November 2011
4.6.1.1 REVIEW ARTICLE
4.6.1.1.1 The Effects on Cordal and Leaflet Stiffness of Severe Apical, Posterior, and Outward Papillary Displacement in Advanced Ventricular Mechanism Heart Failure and Mitral Insufficiency
4.6.1.2 MITRAL VALVE DISEASE
4.6.1.2.1 Interatrial Block and P-Terminal Force: A Reflection of Mitral Stenosis Severity on Electrocardiography
4.6.1.2.2 Surgery for Non-Rheumatic Calcific Mitral Stenosis
4.6.1.2.3 Echocardiographic Right Ventricular Function Assessment Before and After Successful Percutaneous Mitral Commissurotomy
4.6.1.3 AORTIC VALVE DISEASE
4.6.1.3.1 The Combined Impact of Postoperative Heart Failure and EuroSCORE on Long-Term Outcome after Surgery for Aortic Stenosis
4.6.1.3.2 One-Year Observation of Inflammatory Markers in Patients with Aortic Valve Stenosis
4.6.1.3.3 Mini-Sternotomy Aortic Valve Replacement: Is it Safe and Effective? Comparison with Standard Techniques
4.6.1.4 TRICUSPID VALVE DISEASE
4.6.1.4.1 Simulation of Functional Tricuspid Regurgitation Using an Isolated Porcine Heart Model
4.6.1.5 DEVICE EVALUATION
4.6.1.5.1 Importance of Shear in Prosthetic Valve Closure Dynamics
4.6.1.5.2 Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up
4.6.1.5.3 Ten-Year Follow Up after Prospectively Randomized Evaluation of Stentless versus Conventional Xenograft Aortic Valve Replacement
4.6.1.5.4 Pulmonary Homograft Morphology after the Ross Procedure: A Computed Tomography Study
4.6.1.5.5 European Multicenter Study with the Soprano Valve for Aortic Valve Replacement: One-Year Clinical Experience and Hemodynamic Data
4.6.1.5.6 The Freedom SOLO Valve: Mid-Term Clinical Results with a Stentless Pericardial Valve for Aortic Valve Replacement
4.6.1.6 CASE REPORTS
4.6.1.6.1 Transapical Aortic Valve Implantation and ‘Off-Pump’ Arterial Coronary Bypass in a Patient with a Porcelain Aorta
4.6.1.6.2 Aortic Valve ‘Kissing’ Vegetation: Mitral Valve Endocarditis with Functional Aortic Stenosis
4.6.1.6.3 Post-Traumatic Blunt Mitral Insufficiency: Surgical Experience and Review
4.6.1.6.4 Type A Quadricuspid Aortic Valve and Ascending Aorta Aneurysm: A Rare Combination
4.6.1.7 LETTER TO THE EDITOR
4.6.1.7.1 Textile Heart Valve: First Implantation In Vivo
4.6.1.8 IMAGE OF THE MONTH
4.6.1.8.1 Double-Orifice Mitral Valve with Bicuspid Aortic Valve
4.6.2 Volume 20 Number 5 September 2011
4.6.2.1 REVIEW ARTICLES, 4TH FLORIDA VALVE SYMPOSIUM
4.6.2.1.1 Editorial Bridging the Gap from Innovation to Implementation: Proceedings from the 4th Florida Valve Symposium
4.6.2.1.2 Review Quantitative Echocardiographic Assessment of Native Mitral Regurgitation: Two- and Three-Dimensional Techniques
4.6.2.1.3 Past, Present, and Future of Minimally Invasive Mitral Valve Surgery
4.6.2.1.4 Review Transcatheter Aortic Valve Implantation: Complications and Management
4.6.2.2 ANTICOAGULATION
4.6.2.2.1 A Low-Volume Tester for the Thrombogenic Potential of Mechanical Heart Valve Prostheses
4.6.2.2.2 Results of the First Randomized French Study Evaluating Self-Testing of the International Normalized Ratio
4.6.2.2.3 Successful Thrombolysis of Late, Non-Obstructive Mitral Bioprosthetic Valve Thrombosis: Case Report and Review of the Literature
4.6.2.3 AORTIC VALVE DISEASE
4.6.2.3.1 Left Ventricular Remodeling, Hemodynamics and Early Clinical Outcomes after Aortic Valve Replacement with the Pericarbon Freedom Stentless Bioprosthesis: Results from the Italian Prospective Multicenter Trial
4.6.2.3.2 The Value of Intraoperative Transesophageal Echocardiography in Patients Undergoing Aortic Valve Replacement
4.6.2.3.3 Statin treatment and gene expression of anti-atherogenic factor C-type natriuretic peptide system in stenotic aortic valves
4.6.2.3.4 Echocardiographic Patterns of Incomplete Shone’s Syndrome in Adults
4.6.2.4 MITRAL VALVE DISEASE
4.6.2.4.1 Incremental Prognostic Value of Echocardiography in Patients with Prior Mitral Valve Surgery
4.6.2.5 TRICUSPID VALVE DISEASE
4.6.2.5.1 Functional Tricuspid Valve Regurgitation in Adults with Congenital Heart Disease: An Emerging Problem
4.6.2.6 DEVICE EVALUATION
4.6.2.6.1 Cryopreserved Homograft in the Ross Procedure: Outcomes and Prognostic Factors
4.6.2.6.2 Antibiotic Pretreatment of Heart Valve Prostheses to Prevent Early Prosthetic Valve Endocarditis
4.6.2.7 HOW TO DO IT
4.6.2.7.1 Polyester Mesh: An Alternative Material for Reinforcing the Pulmonary Autograft Root
4.6.2.7.2 Designing a Stentless Valve Conduit for Use in a Biological Bentall Procedure
4.6.2.7.3 Alternative Valve-in-Root Concepts for Redo Procedures
4.6.2.8 CASE REPORTS
4.6.2.8.1 Pneumococcal Endocarditis with Extremely Rapid Valve Destruction in a Splenectomized Host
4.6.2.8.2 Myxoma on a Mechanical Mitral Valve Annulus
4.6.2.8.3 Successful Balloon Mitral Valvotomy in Rheumatic Mitral Stenosis with Ebstein’s Anomaly
4.6.2.8.4 Unusual Complication after Aortic Valve Replacement with the Freedom™ Solo Stentless Bioprosthesis
4.6.2.9 IMAGE OF THE MONTH
4.6.2.9.1 A Valid Option for Complex Reoperations on the Ascending Aorta
4.6.3 Volume 20 Number 4 July 2011
4.6.3.1 REVIEW ARTICLE
4.6.3.1.1 Review Heyde’s Syndrome: A Critical Review of the Literature
4.6.3.2 AORTIC VALVE DISEASE
4.6.3.2.1 Editorial Sound Pressure Analysis for the Early Detection of Prosthetic Valve Obstruction
4.6.3.2.2 In-Vitro Detection of Thrombotic Formation on Bileaflet Mechanical Heart Valves
4.6.3.2.3 Individualized Thoracic Aortic Replacement for the Aortopathy of Bicuspid Aortic Valve Disease
4.6.3.2.4 Barriers to Surgery in Severe Aortic Stenosis Patients with Class I Indications for Aortic Valve Replacement
4.6.3.2.5 Thrombocytopenia Following Implantation of the Stentless Biological Sorin Freedom SOLO Valve
4.6.3.3 MITRAL VALVE DISEASE
4.6.3.3.1 Non-Resectional Repair of Myxomatous Mitral Valve Disease: The ‘American Correction’
4.6.3.3.2 Invited Comment Re: Spratt J. Non-Resectional Repair of Myxomatous Mitral Valve Disease: The ‘American Correction’. J Heart Valve Dis 2011; 20:407-414
4.6.3.3.3 Left Atrial Appendage Function in Mitral Stenosis: Is It Determined by Cardiac Rhythm?
4.6.3.4 DEVICE EVALUATION
4.6.3.4.1 Reoperations After the Ross Procedure in Adults: Towards Autograft-Sparing/Ross Reversal
4.6.3.4.2 The CryoLife-O’Brien Stentless Replacement Aortic Valve: Patterns of Valve Failure
4.6.3.4.3 Durability of the Liotta Porcine Bioprosthesis Beyond Two Decades
4.6.3.5 TISSUE ENGINEERING
4.6.3.5.1 Prediction of Oxygen Distribution in Aortic Valve Leaflet Considering Diffusion and Convection
4.6.3.5.2 Can Valvular Interstitial Cells Become True Osteoblasts? A Side-by-Side Comparison
4.6.3.6 HOW TO DO IT
4.6.3.6.1 ‘Clover Technique’ for Tricuspid Regurgitation due to Pacemaker Lead
4.6.3.6.2 Side-Wire Technique for Percutaneous Pulmonary Balloon Valvuloplasty
4.6.3.7 CASE REPORTS
4.6.3.7.1 Infective Endocarditis Presenting with ST Segment Elevation
4.6.3.7.2 Left Ventricular Dysfunction Mimicking Takotsubo Cardiomyopathy Following Cardiac Surgery
4.6.3.7.3 Disc Wear and Entrapment in a Starr-Edwards Mitral Caged-Disc Valve
4.6.3.8 LETTERS TO THE EDITOR
4.6.3.8.1 Prolonged Anticoagulation with Fondaparinux for Mechanical Cardiac Valves in the Setting of Intracranial Hemorrhage
4.6.3.8.2 Beta-Blocker for Severe Aortic Regurgitation?
4.6.3.9 IMAGE OF THE MONTH
4.6.3.9.1 Pulmonary Artery Aneurysm
4.6.4 Volume 20 Number 3 May 2011
4.6.4.1 REVIEW ARTICLE
4.6.4.1.1 Beta-Blocker Therapy for Valvular Disorders
4.6.4.2 MITRAL VALVE DISEASE
4.6.4.2.1 Editorial Valve Repair for Rheumatic Mitral Regurgitation: Still worthwhile?
4.6.4.2.2 Rheumatic Mitral Valve Repair: 22-Year Clinical Results
4.6.4.2.3 Mitral Valve Repair versus Replacement in the Elderly Population
4.6.4.2.4 Outcome and Improvement Predictors of Mitral Regurgitation After Transcatheter Aortic Valve Implantation
4.6.4.3 AORTIC VALVE DISEASE
4.6.4.3.1 Editorial Severe Aortic Stenosis: A Neglected Malignant Disorder and Strategies to Improve Outcomes
4.6.4.3.2 Prevalence and Characteristics of Unoperated Patients with Severe Aortic Stenosis
4.6.4.3.3 Predictors of Rapid Aortic Dilatation in Adults with a Bicuspid Aortic Valve
4.6.4.3.4 Editorial Understanding the Catheter-Doppler Pressure Gradient Discrepancy in Aortic Stenosis
4.6.4.3.5 Low-Flow Severe Aortic Stenosis with Preserved Ejection Fraction, N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) and Cardiovascular Remodeling
4.6.4.4 DEVICE EVALUATION
4.6.4.4.1 Editorial Thrombocytopenia after AVR
4.6.4.4.2 Thrombocytopenia after Aortic Valve Replacement with the Sorin Freedom Solo Prosthesis
4.6.4.4.3 Clinical and Hemodynamic Outcomes after Aortic Valve Replacement with Stented and Stentless Pericardial Xenografts: A Propensity-Matched Analysis
4.6.4.4.4 Hemodynamic Performance of the St. Jude Medical Epic™ Supra Aortic Stented Valve
4.6.4.4.5 The Ross Full Root Replacement in Adults with Bicuspid Aortic Valve Disease
4.6.4.4.6 Right Ventricular Outflow Tract Reconstruction with Decellularized Porcine Xenografts in Patients with Congenital Heart Disease
4.6.4.5 CASE REPORTS
4.6.4.5.1 Mitral and Aortic Valvular Disease Associated with Benfluorex Use
4.6.4.5.2 Mitral Valve Perforation Appearing Years after Radiofrequency Ablation
4.6.4.5.3 A Case of Tropheryma whipplei Infective Endocarditis of the Aortic and Mitral Valves in Association with Psoriatic Arthritis and Lumbar Discitis
4.6.4.5.4 Large Atrial Myxoma Causing Mitral Obstruction and Severe Pulmonary Hypertension
4.6.4.6 LETTERS TO THE EDITOR
4.6.4.6.1 Long-Term Immunesuppressive Treatment of Pemphigus Vulgaris as a Predisposing Factor for Native Valve Endocarditis: Report of Two Cases
4.6.4.6.2 Acute Mitral Regurgitation Complicating Transcatheter Aortic Valve Implantation
4.6.4.6.3 Bilateral Carotid Atherosclerosis: An Inevitable Consequence of Homozygous Familial Hypercholesterolemia
4.6.4.7 IMAGE OF THE MONTH
4.6.4.7.1 Traumatic Tricuspid Regurgitation
4.6.5 Volume 20 Number 2 March 2011
4.6.5.1 REVIEW ARTICLES
4.6.5.1.1 Real-Time Three-Dimensional Transesophageal Echocardiography Assessment of the Mitral Valve: Perioperative Advantages and Game-Changing Findings
4.6.5.1.2 The Role of Shear Stress in the Pathogenesis of Discrete Subaortic Stenosis: Implications for Surgical Treatment
4.6.5.2 MITRAL VALVE DISEASE
4.6.5.2.1 Surgery for Ischemic Mitral Regurgitation: Should the Valve be Repaired?
4.6.5.2.2 Intraventricular and Papillary Muscle Dyssynchrony is Related to the Diastolic Phase of Functional Mitral Regurgitation in Patients with Non-Ischemic Dilated Cardiomyopathy
4.6.5.2.3 Large Atrial Thrombus Formation after MitraClip™ Implantation: Is Anticoagulation Mandatory?
4.6.5.3 AORTIC VALVE DISEASE
4.6.5.3.1 Geometry and Fusion of Aortic Valves from Pulsatile Flow Ventricular Assist Device Patients
4.6.5.3.2 Potential Role of Reynolds Number in Resolving Doppler- and Catheter-Based Transvalvular Gradient Discrepancies in Aortic Stenosis
4.6.5.3.3 Side-Specific Expression of Activated Leukocyte Adhesion Molecule (ALCAM; CD166) in Pathosusceptible Regions of Swine Aortic Valve Endothelium
4.6.5.3.4 Aortic Valve Repair of Non-Penetrating Traumatic Aortic Regurgitation
4.6.5.4 HOW TO DO IT
4.6.5.4.1 Simple Active Air Evacuation Procedure for Right Ventricular Failure Caused by Intracoronary Air Embolism
4.6.5.4.2 Redo Aortic Valve Surgery with Endovascular Control of the Internal Thoracic Artery Graft
4.6.5.4.3 Simple Supra-annular Prosthesis Insertion for Dialysis Patients with Extensive Mitral Annular Calcification
4.6.5.4.4 Creation of a Tricuspid Valve Regurgitation Model from Tricuspid Annular Dilatation using the Cardioport Video-Assisted Imaging System
4.6.5.4.5 Traction Suture Modification of the Cosgrove Hemisternotomy Technique
4.6.5.5 DEVICE PERFORMANCES
4.6.5.5.1 Long-Term Performance of the Hancock Bioprosthetic Valved Conduit in the Aortic Root Position
4.6.5.5.2 Morphologic and Angiographic Analysis to Assess the Safety of a Biodegradable Mitral Annuloplasty Ring
4.6.5.5.3 A Biodegradable Ring Enables Growth of the Native Tricuspid Annulus
4.6.5.6 OVERVIEW STUDIES
4.6.5.6.1 Multidetector-Row Computed Tomography Imaging Characteristics of Mechanical Prosthetic Valves
4.6.5.6.2 Characteristics and Prognosis of Patients Requiring Valve Surgery During Active Infective Endocarditis
4.6.5.7 CASE REPORTS
4.6.5.7.1 Left Atrial Angiosarcoma: An Unusual Presentation and Location
4.6.5.7.2 Inherited Hyper-Homocysteinemia as a Cause of Non-Bacterial Thrombotic Endocarditis
4.6.5.7.3 Severe Mitral Regurgitation in an Adult Patient with Cor Triatriatum
4.6.5.7.4 Sequential Single-Stage Percutaneous Balloon Dilatation of an Inferior Vena Cava Obstruction with Rheumatic Mitral Stenosis
4.6.5.8 IMAGE OF THE MONTH
4.6.5.8.1 Multifocal Papillary Fibroelastoma of the Mitral Valve Complex and Left Ventricle Wall Symptomatic with Systemic Embolization
4.6.6 Volume 20 Number 1 January 2011
4.6.6.1 MITRAL VALVE DISEASE
4.6.6.1.1 A Simple Non-Invasive Method to Predict the Mitral Valve Geometric Orifice Area after Edge-to-Edge Repair
4.6.6.1.2 Edge-to-Edge Repairs of P2 Prolapsed Mitral Valves in Isolated Swine Hearts
4.6.6.1.3 Assessment of Planimetric Mitral Valve Area Using 16-Row Multidetector Computed Tomography in Patients with Rheumatic Mitral Stenosis
4.6.6.2 AORTIC VALVE DISEASE
4.6.6.2.1 The Influence of Statins on Levels of Calcification Biomarkers in Patients with Aortic Sclerosis or Mild Aortic Stenosis
4.6.6.2.2 Prevalence and Clinical Impact of Left Coronary Dominance in Patients with Aortic Stenosis
4.6.6.2.3 Degeneration and Atherosclerosis Inducing Increased Deposition of Type IIA secretory phospholipase A2, C-Reactive Protein and Complement in Aortic Valves Cause Neutrophilic Granulocyte Influx
4.6.6.3 REPLACEMENT DEVICES
4.6.6.3.1 REVIEW Anticalcification Strategies to Increase Bioprosthetic Valve Durability
4.6.6.3.2 Finite Element Modeling of the Pulmonary Autograft at Systemic Pressure before Remodeling
4.6.6.3.3 In-Vitro Investigation of the Hemodynamics of the Edwards Sapien™ Transcatheter Heart Valve
4.6.6.3.4 Correction of Aortic Regurgitation after Transcatheter Aortic Valve Implantation of the Medtronic CoreValve™ Prosthesis Due to a Too-Low Implantation, Using Transcatheter Repositioning
4.6.6.4 MISCELLANEOUS
4.6.6.4.1 First Experimental Use of Magnets in Cardiac Valve Repair
4.6.6.4.2 Triple-Valve Surgery: Clinical Results of a Three-Decade Experience
4.6.6.4.3 Electrocardiographic and Imaging Predictors for Permanent Pacemaker Requirement after Transcatheter Aortic Valve Implantation
4.6.6.5 CASE REPORTS
4.6.6.5.1 Left Ventricular Remodeling with Intensive Exercise after Aortic Valve Replacement
4.6.6.5.2 Bartonella henselae Endocarditis of Percutaneously Implanted Pulmonary Valve: A Case Report
4.6.6.5.3 Valve-Sparing Surgery for Isolated Cleft Mitral Valve Complicated by Endocarditis in a Child
4.6.6.5.4 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography-Negative Endocarditis Lenta caused by Bartonella henselae
4.6.6.5.5 Mitral Valve Reconstruction in a Patient with Libman-Sacks Endocarditis: A Case Report
4.6.6.6 LETTERS TO THE EDITOR
4.6.6.6.1 Endocarditis due to Gemella haemolysans in a Patient with Systemic Lupus Erythematosus
4.6.6.6.2 Rapidly Progressive Infective Endocarditis without Features of Systemic Inflammation Resulting in Perforation of the Native Aortic Valve
4.6.6.6.3 Destructive Abiotrophia defectiva Endocarditis
4.6.6.6.4 Combined Mitral and Pulmonary Valvotomy with Inoue Balloon in Rheumatic Quadrivalvular Disease
4.7 2010
4.7.1 Volume 19 Number 6 November 2010
4.7.1.1 EPIDEMIOLOGY
4.7.1.1.1 Unicuspid Aortic Valve in Children: A Systematic Review Spanning Four Decades
4.7.1.1.2 Risk Model of Valve Surgery in Japan Using the Japan Adult Cardiovascular Surgery Database
4.7.1.2 MITRAL VALVE DISEASE
4.7.1.2.1 Does Down-Sized Ring Annuloplasty Induce Papillary Muscle Relocation in Ischemic Mitral Regurgitation?
4.7.1.2.2 Mitral Valve Annulus Tension and the Mechanism of Annular Dilation: An In-Vitro Study
4.7.1.2.3 Pulmonary Hypertension and Elevated Transpulmonary Gradient in Patients with Mitral Stenosis
4.7.1.3 AORTIC VALVE DISEASE
4.7.1.3.1 Comparison of Serum Troponin I and Plasma Lactate Concentrations in Arrested Versus Beating-Heart Aortic Valve Replacement
4.7.1.3.2 Invited Commentary
4.7.1.3.3 Endothelin-1 and Brain Natriuretic Peptide Plasma Levels Decrease After Aortic Surgery
4.7.1.3.4 Predictors for Late Insufficiency of the Neo-Aortic Valve after the Switch Procedure
4.7.1.4 MOLECULAR BIOLOGY
4.7.1.4.1 Induction of Mesenchymal to Endothelial Transformation of Adipose-Derived Stem Cells
4.7.1.4.2 Association Between Antibodies Against Calcifying Nanoparticles and Mitral Annular Calcification
4.7.1.4.3 Tissue-Gel Electrophoresis Enhances Antigen Removal from Porcine Aortic Valve and Bovine Pericardium
4.7.1.4.4 Functional Characterization of Fibronectin-Separated Valve Interstitial Cell Subpopulations in Three-Dimensional Culture
4.7.1.4.5 Heart Valve Collagens: Cross-Species Comparison Using Immunohistological Methods
4.7.1.5 MISCELLANEOUS
4.7.1.5.1 Clinical Experience with the ATS 3F Stentless Aortic Bioprosthesis: Five Years’ Follow Up
4.7.1.5.2 Mitigation of Calcification and Cytotoxicity of a Glutaraldehyde-Preserved Bovine Pericardial Matrix: Improved Biocompatibility After Extended Implantation in the Subcutaneous Rat Model
4.7.1.5.3 The Effect of Amiodarone on Cardiac Rhythm after Cardiopulmonary Bypass in Patients with Atrial Fibrillation
4.7.1.6 CASE REPORTS
4.7.1.6.1 Mitral Valve Replacement in Pregnancy: A Successful Strategy for Fetal Survival
4.7.1.6.2 A Previously Undescribed Type of Quadricuspid Aortic Valve: Type H
4.7.1.6.3 Mitral Valve Replacement in a Case of Dextrocardia with Situs Solitus
4.7.1.6.4 Severe Tricuspid Regurgitation in a Patient Receiving Low-Dose Cabergoline for the Treatment of Acromegaly
4.7.1.6.5 Acquired Left Ventricular-Right Atrial Communication Following Mitral Valve Replacement
4.7.1.6.6 Repair of Hammock Mitral Valve with Hypoplastic Posterior Leaflet in an Adult
4.7.1.7 LETTERS TO THE EDITOR
4.7.1.7.1 Underdiagnosis of the Severity of Mitral Regurgitation in Left Atrial Myxoma
4.7.1.7.2 Transcatheter Implantation of the Tricuspid Valve in the Inferior Vena Cava: An Experimental Study
4.7.1.7.3 Giant Left Ventricular Aneurysm 20 Years after Mitral Valve Replacement: A Very Rare Complication
4.7.1.7.4 Giant Aortic Aneurysm after 35 Years’ Uneventful Survival, without Anticoagulation, with a Björk-Shiley Aortic Valve
4.7.1.7.5 The Use of Granulocyte Colony-Stimulating Factor does not Appear to Reduce Recovery Time in Penicillin-Related Agranulocytosis during the Treatment of Endocarditis
4.7.1.8 IMAGE OF THE MONTH
4.7.1.8.1 Papillary Fibroelastoma of the Aortic Valve: Appearance in Echocardiography, Computed Tomography, and Histopathology
4.7.2 Volume 19 Number 5 September 2010
4.7.2.1 CURRENT REVIEW OF BIOPROSTHETIC VALVES
4.7.2.1.1 Invited Review: Transcatheter Valves: A Brave New World
4.7.2.1.2 Current Opinion: Assessment of Structural Valve Deterioration Extended to 20 Years – Review of Documentation on the St. Jude Medical Bioprostheses
4.7.2.1.3 The Fate of Bioprostheses in Middle-Aged Patients: The Japanese Experience
4.7.2.2 MITRAL VALVE DISEASE
4.7.2.2.1 Frequency and Surgical Management of Complex Posterior Leaflet Prolapse of the Mitral Valve
4.7.2.2.2 E/(Ea×Sa) Estimates Left Ventricular End-Diastolic Pressure in Patients with Severe Mitral Regurgitation
4.7.2.2.3 Recellularization of Decellularized Mitral Heart Valves in Juvenile Pigs
4.7.2.2.4 Complex Repair of a Barlow’s Valve Using the Da Vinci Robotic Surgical System
4.7.2.2.5 Architecture of a Native Mitral Valve Thrombus in a Patient with Hypereosinophilic Syndrome
4.7.2.3 AORTIC VALVE DISEASE
4.7.2.3.1 Medicolegal Characteristics of Aortic Stenosis Litigation: A Review of the LexisNexis Academic Database
4.7.2.3.2 Invited editorial comment
4.7.2.3.3 Propensity Score-Matched Analysis of Aortic Valve Replacement by Mini-Thoracotomy
4.7.2.3.4 Aortic Valve Replacement in Octogenarians: Analysis of Risk Factors for Early and Late Mortality
4.7.2.3.5 Visualization by 256-Slice Computed Tomography of Mycotic Aortic Root Aneurysms in Infective Endocarditis
4.7.2.4 DIAGNOSTIC PROCEDURES IN HEART VALVE DISEASE
4.7.2.4.1 Organ Culture as a Tool to Identify Early Mechanisms of Serotonergic Valve Disease
4.7.2.4.2 Association of Serum Fetuin-A with Valvular Calcium Concentration in Rheumatic Mitral Valve Disease
4.7.2.5 MISCELLANEOUS
4.7.2.5.1 Mid-Term Follow Up of Triple Valve Surgery in a Western Community: Predictors of Survival
4.7.2.5.2 An Agonist of Liver X Receptor Slows Valvular Disease in a Hypercholesterolemia Mouse Model
4.7.2.6 CASE REPORTS
4.7.2.6.1 Usefulness of Computed Tomography Scanning in the Diagnosis of Aortic Prosthetic Valve Pannus
4.7.2.6.2 Lambl’s Excrescences: A Rare Cause of Stroke
4.7.2.7 IMAGE OF THE MONTH
4.7.2.7.1 Compression of the Left Coronary Arteries by a Large Pseudoaneurysm as a Late Complication after Surgical Treatment of Aortic Valve Endocarditis
4.7.2.8 LETTERS TO THE EDITOR
4.7.2.8.1 No Arterial Access: A ‘Blind Flight’ for a Transapical Aortic Valve Implantation
4.7.2.8.2 Bioprosthetic Tricuspid Valve Implantation for Active Tricuspid Valve Endocarditis in an Adult Burn Patient
4.7.2.8.3 Another Cause of Severe Aortic Regurgitation: Congenital Quadricuspid Aortic Valve
4.7.2.8.4 Acquired Left Ventricular-Right Atrial Communication Following Mitral Valve Replacement
4.7.3 Volume 19 Number 4 July 2010
4.7.3.1 MITRAL VALVE DISEASE
4.7.3.1.1 Is Early Antithrombotic Therapy Necessary after Tissue Mitral Valve Replacement?
4.7.3.1.2 Tricuspid Regurgitation in Patients with Severe Mitral Regurgitation and Normal Left Ventricular Ejection Fraction: Risk Factors and Prognostic Implications in a Cohort of 895 Patients
4.7.3.1.3 Determinants of Evolution and Progression of Acute Ovine Ischemic Mitral Regurgitation
4.7.3.1.4 Echocardiographic Assessment of the Effects of Mitral Valve Repair on Mitral Valve Geometry in Rheumatic Mitral Stenosis
4.7.3.1.5 Acute Mitral Valve Endocarditis Complicated by Right Atrial Fistula in Beta-Thalassemia Major
4.7.3.2 AORTIC VALVE DISEASE
4.7.3.2.1 Editorial: How Can We Logically Describe the Components of the Arterial Valves?
4.7.3.2.2 Review: Insights into the Use of Biomarkers in Calcific Aortic Valve Disease
4.7.3.2.3 Paraoxonase Activity Might be Predictive of the Severity of Aortic Valve Stenosis
4.7.3.2.4 Altered MicroRNAs in Bicuspid Aortic Valve: A Comparison Between Stenotic and Insufficient Valves
4.7.3.2.5 Relationship Between Aortic Valve Calcification and the Severity of Coronary Atherosclerotic Disease
4.7.3.3 DEVICE EVALUATION
4.7.3.3.1 Editorial: Long-Term Follow Up of Patients Undergoing Reoperative Surgery with Aortic or Mitral Valve Replacement, Using a St. Jude Medical Prosthesis
4.7.3.3.2 Long-Term Follow Up of Patients Undergoing Reoperative Surgery with Aortic or Mitral Valve Replacement Using a St. Jude Medical Prosthesis
4.7.3.3.3 The Changing Hydrodynamic Performance of the Decellularized Intact Porcine Aortic Root: Considerations on In-Vitro Testing
4.7.3.3.4 Leaflet Opening and Closing Dynamics of Stentless Bioprostheses
4.7.3.3.5 In-Vivo Assessment of a Novel Polymer (SIBS) Trileaflet Heart Valve
4.7.3.3.6 In-Vitro Seeding of Human Umbilical Cord Vein Endothelial Cells on Hydroxyapatite for Mechanical Heart Valve Applications
4.7.3.4 LONG TERM OUTCOME
4.7.3.4.1 Determinants of Short- and Long-Term Outcomes Following Triple Valve Surgery
4.7.3.4.2 Quality of Life Following Heart Valve Replacement in the Elderly
4.7.3.5 HOW TO DO IT
4.7.3.5.1 Left Ventricular Myxoma Resection with Minimally Invasive Mitral Valve Reconstruction
4.7.3.5.2 A Novel Technique of Coronary Reconstruction During Complex Aortic Root Replacement
4.7.3.6 LETTERS TO THE EDITOR
4.7.3.6.1 Recidivant Endocarditis: Report of Two Cases
4.7.3.6.2 Does Isolated Annular Dilatation Cause Hemodynamically Significant Mitral Regurgitation?
4.7.3.6.3 Response
4.7.4 Volume 19 Number 3 May 2010
4.7.4.1 DEVICE EVALUATION
4.7.4.1.1 Superior Results Following the Ross Procedure in Patients with Congenital Heart Disease
4.7.4.1.2 Clinical Experience with Expanded Use of the Ross Procedure: A Paradigm Shift?
4.7.4.1.3 The First Fifty Consecutive Bentall Operations with a Prefabricated Tissue-Valved Aortic Conduit: A Single-Center Experience
4.7.4.1.4 In-Vivo Blood Velocity and Velocity Gradient Profiles Downstream of Stented and Stentless Aortic Heart Valves
4.7.4.1.5 Mitral Valve Replacement with the Quattro Stentless Pericardial Bioprosthesis: Mid-Term Clinical and Echocardiographic Follow Up
4.7.4.2 INFECTIVE ENDOCARDITIS
4.7.4.2.1 Infective Endocarditis in Patients with Diabetes Mellitus
4.7.4.2.2 Considerations in Timing of Surgical Intervention for Infective Endocarditis with Cerebrovascular Complications
4.7.4.3 POSTOPERATIVE OUTCOME
4.7.4.3.1 Short-Term Results of Repeat Valve Replacement: A Predictive Factor Analysis
4.7.4.3.2 Sildenafil and Beraprost Combination Therapy in Patients with Pulmonary Hypertension Undergoing Valvular Heart Surgery
4.7.4.3.3 Simultaneous Aortic and Mitral Valve Replacement in Children: Time-Related Outcomes and Risk Factors
4.7.4.4 MRI ASSESSMENT IN HEART VALVE DISEASE
4.7.4.4.1 Aortic Dilatation in Patients with Prosthetic Aortic Valve: Comparison of MRI and Echocardiography
4.7.4.4.2 Planimetry of Mitral Valve Stenosis in Rheumatic Heart Disease by Magnetic Resonance Imaging
4.7.4.5 HOW TO DO IT
4.7.4.5.1 Modified Repair in Patients with Ebstein’s Anomaly
4.7.4.5.2 Supra-Annular Stitch to Avoid Distortion of the Right Coronary Cusp in Aortic Root Resuspension
4.7.4.6 MISCELLANEOUS
4.7.4.6.1 Rheumatic Tricuspid Valve Disease: An Evidence-Based Systematic Overview
4.7.4.6.2 Pilot Licensing after Aortic Valve Surgery
4.7.4.6.3 The Association of Heart Valve Diseases with Coronary Artery Dominance
4.7.4.6.4 Thrombocytopenia after Aortic Valve Replacement: Comparison Between Mechanical and Biological Valves
4.7.4.7 LETTERS TO THE EDITOR
4.7.4.7.1 Puerperal Endocarditis in an Adult Woman with Congenital Heart Disease: A Case Report
4.7.4.7.2 Balloon Dilatation of Rheumatic Tricuspid Stenosis
4.7.4.7.3 Spontaneous Resolution of Severe Hemolysis After Valve Surgery
4.7.4.7.4 Another Cause of Severe Aortic Regurgitation: Congenital Quadricuspid Aortic Valve
4.7.5 Volume 19 Number 2 March 2010
4.7.5.1 VALVE THROMBOSIS
4.7.5.1.1 Treatment of Prosthetic Valve Thrombosis: Rationale for a Prospective Randomized Clinical Trial
4.7.5.2 AORTIC VALVE DISEASE
4.7.5.2.1 Relationship between Prosthesis-Patient Mismatch and Pro-Brain Natriuretic Peptides after Aortic Valve Replacement
4.7.5.2.2 Aortic Root Reoperation: A Technical Challenge
4.7.5.2.3 Transapical Implantation of a Novel Self-Expanding Sutureless Aortic Valve Prosthesis
4.7.5.3 TRICUSPID VALVE DISEASE
4.7.5.3.1 Minimally Invasive Isolated Tricuspid Valve Surgery
4.7.5.3.2 Tricuspid Valve Replacement with Mechanical Prostheses: Long-Term Results
4.7.5.3.3 Thoracoscopic and Robotic Tricuspid Valve Annuloplasty with a Biodegradable Ring: An Initial Experience
4.7.5.4 INFECTIVE ENDOCARDITIS
4.7.5.4.1 Surgery for Active Infective Mitral Valve Endocarditis: A 20-Year, Single-Center Experience
4.7.5.4.2 Risk Factors for In-Hospital Mortality in Infective Endocarditis: Five Years’ Experience at a Tertiary Care Hospital in Turkey
4.7.5.4.3 A Rare Complication of Infective Endocarditis: Left Main Coronary Artery Embolization Resulting in Sudden Death
4.7.5.5 LATE OUTCOME
4.7.5.5.1 Heart Valve Sound of Various Mechanical Composite Grafts, and the Impact on Patients’ Quality of Life
4.7.5.5.2 Malpositioned Mechanical Mitral Valves Causing Left Ventricular Outflow Tract Obstruction
4.7.5.6 MISCELLANEOUS
4.7.5.6.1 Minimally Invasive Right Lateral Thoracotomy without Aortic Cross-Clamping: An Attractive Alternative to Repeat Sternotomy for Reoperative Mitral Valve Surgery
4.7.5.6.2 Annular Excursion Contributes to Efficient Cardiac Output: A Three-Dimensional Echocardiographic Approach
4.7.5.7 HOW TO DO IT
4.7.5.7.1 A Method to Avoid Knot-Tying in Artificial Chordae Implantation for Mitral Valve Repair
4.7.5.7.2 A Modified David Technique in Endocarditis with Multiple Paravalvular Abscesses
4.7.5.8 CASE REPORTS
4.7.5.8.1 Mitral Stenosis due to Pannus Overgrowth after Rigid Ring Annuloplasty
4.7.5.8.2 Surgical Re-Utilization of a Pulmonary Valve Graft after Failed Percutaneous Treatment
4.7.5.9 LETTERS TO THE EDITOR
4.7.5.9.1 Novel Use of a Percutaneous Aortic Valve in Stentless Bioprosthetic CryoLife-OíBrien Valve Dysfunction